<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>DEPARTMENT OF HEALTH RESPONSE TO</title></head><body><div><p style="margin:0pt"><span style="font-family:Tahoma; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by the Department of Health (BTO0031)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The Department welcomes the opportunity to respon</span><span style="font-family:'Times New Roman'; font-size:11pt">d</span><span style="font-family:'Times New Roman'; font-size:11pt"> to the varied selection of questions posed by the Committee’s inquiry, and to acquaint the Committee with the Department’s actions with regard to the issues raised.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Included is background to </span><span style="font-family:'Times New Roman'; font-size:11pt">Creutzfeldt-Jakob disease (</span><span style="font-family:'Times New Roman'; font-size:11pt">CJD</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt"> and the Department</span><span style="font-family:'Times New Roman'; font-size:11pt">’</span><span style="font-family:'Times New Roman'; font-size:11pt">s related work, and </span><span style="font-family:'Times New Roman'; font-size:11pt">from pa</span><span style="font-family:'Times New Roman'; font-size:11pt">ge </span><span style="font-family:'Times New Roman'; font-size:11pt">13</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">response</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> to the Committee</span><span style="font-family:'Times New Roman'; font-size:11pt">’</span><span style="font-family:'Times New Roman'; font-size:11pt">s specific questions</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Background </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">– </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Transmissible Spongiform Encephalopathies </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">(TSEs)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 20.35pt; orphans:0; padding-left:4.75pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">TSEs, or prion diseases, are a group of very rare degenerative brain disorders characterised in clinical cases by the "spongy" appearance of the brain.  All can have very long incubation periods and cause severe and irreversible damage to the central nervous system.  There are so far no proven effective treatments for any TSE and they are inevitably</span><span style="font-family:'Times New Roman'; font-size:11pt"> fatal.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 20.35pt; orphans:0; padding-left:4.75pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">T</span><span style="font-family:'Times New Roman'; font-size:11pt">SEs </span><span style="font-family:'Times New Roman'; font-size:11pt">include the various forms of CJD and other TSEs in humans, bovine spongiform encephalopathy (BSE) in cattle, scrapie in sheep and goats and chronic wasting disease (CWD) which affects </span><span style="font-family:'Times New Roman'; font-size:11pt">various species of deer in </span><span style="font-family:'Times New Roman'; font-size:11pt">North America.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 20.35pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Studies suggest that TSEs are caused by abnormal prion protein, which when it occurs in a normal form is a harmless protein found in the body's cells.  The harmless and infectious forms of the prion protein are nearly identical, but the infectious form takes on a different folded shape from the normal protein.</span><span style="font-family:'Times New Roman'; font-size:11pt">  This formation contributes to making TSEs difficult diseases to test for, particular</span><span style="font-family:'Times New Roman'; font-size:11pt">ly in asymptomatic individuals.</span></li></ol><p style="background-color:#ffffff; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 20.35pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Sporadic Creutzfeldt-Jakob disease (sCJD), first described in the 1920s, is the most well-known of the human TSEs, </span><span style="font-family:'Times New Roman'; font-size:11pt">and</span><span style="font-family:'Times New Roman'; font-size:11pt"> affects about one in every one million people each year.  Other human TSEs include fatal familial insomnia (FFI), Gerstmann-Straussler-Scheinker disease (GSS)</span><span style="font-family:'Times New Roman'; font-size:11pt"> and kuru</span><span style="font-family:'Times New Roman'; font-size:11pt">.  Kuru, identified in the Fore people of Papua New Guinea and associated with past ritualistic consumption of human tissues</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> has now almost disappeared.  FFI and GSS are rare hereditary diseases, found in just a few families.</span></li></ol><p style="background-color:#ffffff; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 20.35pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The range of human TSEs can occur three ways</span><span style="font-family:'Times New Roman'; font-size:11pt">;</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">most commonly </span><span style="font-family:'Times New Roman'; font-size:11pt">sporadically</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and much less commonly as </span><span style="font-family:'Times New Roman'; font-size:11pt">hereditary diseases</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">or through transmission from infected individuals.  Sporadic TSEs may develop because some of a</span><span style="font-family:'Times New Roman'; font-size:11pt">n individual’s</span><span style="font-family:'Times New Roman'; font-size:11pt">  normal prions spontaneously change into the infectious form of the protein and then alter the prions in other cells in a chain reaction.  Inherited cases arise from a change, or mutation, in the prion protein gene that causes the prions to be shaped in an abnormal way.  This genetic change may be transmitted</span><span style="font-family:'Times New Roman'; font-size:11pt"> to an individual's offspring.</span></li></ol><p style="background-color:#ffffff; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 20.35pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Transmission of TSEs from infected individuals is </span><span style="font-family:'Times New Roman'; font-size:11pt">very </span><span style="font-family:'Times New Roman'; font-size:11pt">rare.</span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">TSEs cannot be transmitted through normal person-to-person contact or through the air.  However, they may be transmitted through contact with </span><span style="font-family:'Times New Roman'; font-size:11pt">certain </span><span style="font-family:'Times New Roman'; font-size:11pt">infected tissue</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt">, body fluids, or medical instruments.  </span><span style="font-family:'Times New Roman'; font-size:11pt">Routine </span><span style="font-family:'Times New Roman'; font-size:11pt">sterili</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt">ation procedures such as </span><span style="font-family:'Times New Roman'; font-size:11pt">heat </span><span style="font-family:'Times New Roman'; font-size:11pt">or irradiat</span><span style="font-family:'Times New Roman'; font-size:11pt">ion </span><span style="font-family:'Times New Roman'; font-size:11pt">do not prevent transmission of TSEs.</span></li></ol><p style="background-color:#ffffff; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="7" type="1" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 20.35pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Symptoms of TSEs vary, but they commonly include personality changes, psychiatric problems such as depression, lack of coordination, and/or an unsteady gait.  In the later stages of the disease, patients have severe mental impairment and lose the ability to move or speak.</span></li></ol><p style="background-color:#ffffff; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="8" type="1" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 20.35pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">A new variety of CJD, called variant CJD (vCJD), was fir</span><span style="font-family:'Times New Roman'; font-size:11pt">st identified when scientists (now</span><span style="font-family:'Times New Roman'; font-size:11pt"> the UK National CJD </span><span style="font-family:'Times New Roman'; font-size:11pt">Research and </span><span style="font-family:'Times New Roman'; font-size:11pt">Surveillance Unit</span><span style="font-family:'Times New Roman'; font-size:11pt"> (</span><span style="font-family:'Times New Roman'; font-size:11pt">CJDRSU</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt"> in</span><span style="font-family:'Times New Roman'; font-size:11pt"> Edinburgh </span><span style="font-family:'Times New Roman'; font-size:11pt">described it in 1996.  The initial symptoms of vCJD are different from those of sCJD and the disorder </span><span style="font-family:'Times New Roman'; font-size:11pt">typically occurs in younger patients.  </span><span style="font-family:'Times New Roman'; font-size:11pt">The e</span><span style="font-family:'Times New Roman'; font-size:11pt">vidence suggests that primary vCJD </span><span style="font-family:'Times New Roman'; font-size:11pt">results</span><span style="font-family:'Times New Roman'; font-size:11pt"> from human consumption of </span><span style="font-family:'Times New Roman'; font-size:11pt">meat</span><span style="font-family:'Times New Roman'; font-size:11pt"> from BSE infected cattle.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">TSEs in the UK</span></p><ol start="9" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 20.35pt; orphans:0; padding-left:4.75pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">BSE has been the most highly publicised of the animal TSEs because of its </span><span style="font-family:'Times New Roman'; font-size:11pt">impact on the UK cattle population and its </span><span style="font-family:'Times New Roman'; font-size:11pt">links to vCJD in humans</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> and its estimated £38 billion cost to the UK economy.  The first case in UK </span><span style="font-family:'Times New Roman'; font-size:11pt">cattle</span><span style="font-family:'Times New Roman'; font-size:11pt"> was identified in 1985 and BSE was recognised as a new disease in 1986.  In 1992 the number of cases in cattle reached a peak of 36,680 and the number has fallen steadily since (there were only </span><span style="font-family:'Times New Roman'; font-size:11pt">3</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">UK </span><span style="font-family:'Times New Roman'; font-size:11pt">cases in 20</span><span style="font-family:'Times New Roman'; font-size:11pt">12</span><span style="font-family:'Times New Roman'; font-size:11pt">).  At the height of the epidemic in British cattle the incidence of BSE was </span><span style="font-family:'Times New Roman'; font-size:11pt">up to </span><span style="font-family:'Times New Roman'; font-size:11pt">1,000 cases per week, and by 2013, more than 181,000 cases had been confirmed in British cattle.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="10" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">When first identified BSE seemed similar to scrapie, a disease in sheep that had been around for 200 years with no apparent effect on human health.  </span><span style="font-family:'Times New Roman'; font-size:11pt">At the time, relatively f</span><span style="font-family:'Times New Roman'; font-size:11pt">ew cattle seemed to be infected, and the possibility that it might be transmissible to humans was regarded by most scientists as remote.  It is now generally agreed that the BSE epidemic in cattle was exacerbated by feeding rendered meat- and bone-meal (MBM) to cattle.  Measures to control the BSE epidemic in cattle were first introduced in 1988 with the ban on feeding MBM and </span><span style="font-family:'Times New Roman'; font-size:11pt">the </span><span style="font-family:'Times New Roman'; font-size:11pt">slaughter </span><span style="font-family:'Times New Roman'; font-size:11pt">of </span><span style="font-family:'Times New Roman'; font-size:11pt">BSE infected cattle</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">  </span><span style="font-family:'Times New Roman'; font-size:11pt">F</span><span style="font-family:'Times New Roman'; font-size:11pt">urther actions in response to BSE followed in the early 1990s.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Variant Creutzfeldt-Jakob disease</span></p><ol start="11" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">vCJD, as described by the </span><span style="font-family:'Times New Roman'; font-size:11pt">CJDRSU</span><span style="font-family:'Times New Roman'; font-size:11pt">, is distinguishable from </span><span style="font-family:'Times New Roman'; font-size:11pt">sporadic</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">CJD </span><span style="font-family:'Times New Roman'; font-size:11pt">in a number of ways.  It tends to affect younger people with an average (median) age of onset of around 26 years (median age at death 28 years).  The predominant initial clinical symptom</span><span style="font-family:'Times New Roman'; font-size:11pt">s are </span><span style="font-family:'Times New Roman'; font-size:11pt">psychiatric or sensory problems, with brain changes </span><span style="font-family:'Times New Roman'; font-size:11pt">leading to </span><span style="font-family:'Times New Roman'; font-size:11pt">coordination problems, dementia and muscle twitching occurring later.  The illness usually lasts between six months and two years before death.  </span><span style="font-family:'Times New Roman'; font-size:11pt">It is inevitably fatal.  </span><span style="font-family:'Times New Roman'; font-size:11pt">The definitive diagnosis of vCJD can only be confirmed by looking at brain tissue</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> usually at post-mortem</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="margin:0pt 0pt 0pt 18pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="12" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">There have been 177 </span><span style="font-family:'Times New Roman'; font-size:11pt">deaths from definite or probable cases of vCJD in the U</span><span style="font-family:'Times New Roman'; font-size:11pt">K </span><span style="font-family:'Times New Roman'; font-size:11pt">and </span><span style="font-family:'Times New Roman'; font-size:11pt">there are now no patients </span><span style="font-family:'Times New Roman'; font-size:11pt">alive with the disease</span><span style="font-family:'Times New Roman'; font-size:11pt">.  The peak year of onset of disease was 1999 and of death was 2000, since when numbers of cases have fallen.  Data on all UK vCJD cases by year of disease onset, diagnosis and deaths are at </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Annex</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">A</span><span style="font-family:'Times New Roman'; font-size:11pt">.  The graph at </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Annex </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">B</span><span style="font-family:'Times New Roman'; font-size:11pt"> shows UK data for date </span><span style="font-family:'Times New Roman'; font-size:11pt">of </span><span style="font-family:'Times New Roman'; font-size:11pt">onsets, diagnosis and deaths for all 17</span><span style="font-family:'Times New Roman'; font-size:11pt">7 UK vCJD cases 1994-2012</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">vCJD: </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Recent history</span></p><ol start="13" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The primary route of vCJD infection, from BSE/cattle to humans, appears to have been resolved through extensive meat hygiene and other controls.  In addition the Department of Health and the UK health services have introduced a significant number of actions, based on available evidence and careful risk assessments, to reduce the potential for secondary (person to person) spre</span><span style="font-family:'Times New Roman'; font-size:11pt">ad of abnormal prion infection </span><span style="font-family:'Times New Roman'; font-size:11pt">associated with clinical vCJD.  Nevertheless considerable scientific uncertainties remain, especially around the prevalence of infection in the wider population and the risk that this may pose for further transmission.</span></li></ol><p style="margin:0pt 0pt 0pt 18pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="14" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">It is therefore important that </span><span style="font-family:'Times New Roman'; font-size:11pt">Government </span><span style="font-family:'Times New Roman'; font-size:11pt">measures continue to:</span></li></ol><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; orphans:0; padding-left:7.94pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">maintain barriers against the possibility of further primary spread;</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; orphans:0; padding-left:7.94pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">ensure proportionate actions to reduce potential risks of secondary infection </span><span style="font-family:'Times New Roman'; font-size:11pt">(</span><span style="font-family:'Times New Roman'; font-size:11pt">via</span><span style="font-family:'Times New Roman'; font-size:11pt"> blood, cell, tissue and organ</span><span style="font-family:'Times New Roman'; font-size:11pt"> donations or surg</span><span style="font-family:'Times New Roman'; font-size:11pt">ical cross contamination)</span><span style="font-family:'Times New Roman'; font-size:11pt"> are in place and kept under regular expert review; and</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; orphans:0; padding-left:7.94pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">support funding for </span><span style="font-family:'Times New Roman'; font-size:11pt">continued </span><span style="font-family:'Times New Roman'; font-size:11pt">surveillance and appropriate research.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="15" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">I</span><span style="font-family:'Times New Roman'; font-size:11pt">n 1996, with strong epidemiological and laboratory evidence for a causal link between vCJD and BSE, the </span><span style="font-family:'Times New Roman'; font-size:11pt">independent expert </span><span style="font-family:'Times New Roman'; font-size:11pt">Spongiform Encephalopathy Advisory Committee (</span><span style="font-family:'Times New Roman'; font-size:11pt">SEAC</span><span style="font-family:'Times New Roman'; font-size:11pt">) </span><span style="font-family:'Times New Roman'; font-size:11pt">concluded that the most likely explanation for the emergence of vCJD was that it had been transmitted to people who had eaten cattle meat, organs or tissue infected with BSE.  In the late 1990s new research provided further evidence that the agent which causes BSE is the same as that which causes vCJD.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="16" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">In December 1997, the then Government set up the Phillips Inquiry into BSE and published its</span><span style="font-family:'Times New Roman'; font-size:11pt"> 16 volume </span><span style="font-family:'Times New Roman'; font-size:11pt">report in </span><span style="font-family:'Times New Roman'; font-size:11pt">October 2000.  The Government </span><span style="font-family:'Times New Roman'; font-size:11pt">response to the report was published in September 2001.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Government f</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">unding</span></p><ol start="17" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">In 2002, following the </span><span style="font-family:'Times New Roman'; font-size:11pt">Phillips Inquiry, a no-fault payment scheme (the vCJD Trust) was established, operated by an independent Board of Trustees, for all vCJD patients and their families.  Compensation for vCJD patients is paid in recognition of their wholly exceptional situation.  The scheme has distributed nearly £41</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">m</span><span style="font-family:'Times New Roman'; font-size:11pt">illion</span><span style="font-family:'Times New Roman'; font-size:11pt"> to patients and their families.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="18" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The Government has an on-going commitment to provide resources for CJD surveillance and research.  This currently includes </span><span style="font-family:'Times New Roman'; font-size:11pt">annual funding of £2</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">m</span><span style="font-family:'Times New Roman'; font-size:11pt">illion</span><span style="font-family:'Times New Roman'; font-size:11pt"> for the </span><span style="font-family:'Times New Roman'; font-size:11pt">CJDRSU, as part of a £5.5</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">m</span><span style="font-family:'Times New Roman'; font-size:11pt">illion</span><span style="font-family:'Times New Roman'; font-size:11pt"> ring-fenced budget for prion research and surveillance funding via the Department’s Policy Research Programme (PRP).  The PRP currently funds amongst others</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> projects on the prevalence of abnormal prion protein, disease surveillance, protein removal techno</span><span style="font-family:'Times New Roman'; font-size:11pt">lo</span><span style="font-family:'Times New Roman'; font-size:11pt">gies and instrument decontamination.</span><span style="font-family:'Times New Roman'; font-size:11pt">  Professor Ironside</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> who has given oral evidence to the Inquiry</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> is based at the CJDRSU.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="19" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The Department also funds a</span><span style="font-family:'Times New Roman'; font-size:11pt"> care package overseen by the </span><span style="font-family:'Times New Roman'; font-size:11pt">CJDRSU to ensure that patients with </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">all forms</span><span style="font-family:'Times New Roman'; font-size:11pt"> of CJD have support in the community, and to provide for those elements of their care that cannot be readily supplied by local health and social services.  </span><span style="font-family:'Times New Roman'; font-size:11pt">Total e</span><span style="font-family:'Times New Roman'; font-size:11pt">xpenditure from th</span><span style="font-family:'Times New Roman'; font-size:11pt">is fund to date exceeds </span><span style="font-family:'Times New Roman'; font-size:11pt">£3</span><span style="font-family:'Times New Roman'; font-size:11pt"> million</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="20" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The Medical Research Council (MRC) has also provided substantial funding for prion research, over £96 million since 1990.  Since 1998 this has included approximately £6 million per annum to the MRC Prion Unit whose Director</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> Professor Collinge</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> has provide</span><span style="font-family:'Times New Roman'; font-size:11pt">d oral evidence to the Inquiry.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Approach to vCJD risk reduction</span></p><ol start="21" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Following identification of the link between BSE and vCJD, successive UK Governments and UK Health Departments have followed a precautionary approach to reduce the risk of contracting vCJD from meat and meat products, and the risk of person</span><span style="font-family:'Times New Roman'; font-size:11pt">-</span><span style="font-family:'Times New Roman'; font-size:11pt">to</span><span style="font-family:'Times New Roman'; font-size:11pt">-</span><span style="font-family:'Times New Roman'; font-size:11pt">person (secondary) transmission of CJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> through clinical interventions</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="22" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Shortly after vCJD was first identified, the possibility of human-to-human transmission via blood was considered, and </span><span style="font-family:'Times New Roman'; font-size:11pt">from the late 1990s onward </span><span style="font-family:'Times New Roman'; font-size:11pt">the Department implemented precautionary measures to reduce what was, at that time, a theoretical risk</span><span style="font-family:'Times New Roman'; font-size:11pt">, starting </span><span style="font-family:'Times New Roman'; font-size:11pt">in December 1997 with the </span><span style="font-family:'Times New Roman'; font-size:11pt">withdrawal</span><span style="font-family:'Times New Roman'; font-size:11pt"> of all blood components, plasma products or tissues obtained from individuals who later developed clinical vCJD.  </span><span style="font-family:'Times New Roman'; font-size:11pt">The measures were tightened as evidence of transmission via blood began to emerge from animal studies.  These measures included removing white blood cells from blood</span><span style="font-family:'Times New Roman'; font-size:11pt"> (leucoreduction or leucodepletion)</span><span style="font-family:'Times New Roman'; font-size:11pt"> in 1999</span><span style="font-family:'Times New Roman'; font-size:11pt">, and importing blood products from countries unaffected by vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> (USA and Austria) from 2004</span><span style="font-family:'Times New Roman'; font-size:11pt">.  An important additional step, introduced in March 2004, was to exclude from blood donation all those who had themselves received a blood transfusion since January 1980</span><span style="font-family:'Times New Roman'; font-size:11pt">.  A</span><span style="font-family:'Times New Roman'; font-size:11pt"> list of </span><span style="font-family:'Times New Roman'; font-size:11pt">current </span><span style="font-family:'Times New Roman'; font-size:11pt">blood risk reduction measures </span><span style="font-family:'Times New Roman'; font-size:11pt">published </span><span style="font-family:'Times New Roman'; font-size:11pt">in December 2013 </span><span style="font-family:'Times New Roman'; font-size:11pt">by </span><span style="font-family:'Times New Roman'; font-size:11pt">the independent scientific Advisory Committee on the Safety of Blood, Tissues and Organs (</span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">is at </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Annex</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> C</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="23" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Whilst there is to date no evidence that vCJD has been transmitted via surgical instruments, there is some </span><span style="font-family:'Times New Roman'; font-size:11pt">historic </span><span style="font-family:'Times New Roman'; font-size:11pt">evidence that sporadic CJD has been transmitted in certain very </span><span style="font-family:'Times New Roman'; font-size:11pt">particular circumstances, such as neurosurgery.  Therefore, the Advisory Committee on Dangerous Pathogens (ACDP) advised from the mid 1990s on the decontamination, quarantining and appropriate use of surgical equipment (including endoscopes), and on pre-surgical assessment of patients to </span><span style="font-family:'Times New Roman'; font-size:11pt">identify</span><span style="font-family:'Times New Roman'; font-size:11pt"> and act on those with, or at risk of, all forms of human prion disease.</span><span style="font-family:'Times New Roman'; font-size:11pt">  Details of the range of guidance published by ACDP is at </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Annex </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">D</span><span style="font-family:'Times New Roman'; font-size:11pt">, and ACDP will be providing additional evidence to the Inquiry</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">  The Chair of ACDP TSE Sub Group, Dr Salmon, has provided oral evidence to the Inquiry.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="24" type="1" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Prions are difficult to remove from instruments and </span><span style="font-family:'Times New Roman'; font-size:11pt">routine washing and sterilisation are unsatisfactory. Therefore, </span><span style="font-family:'Times New Roman'; font-size:11pt">high quality decontamination across surgical and dental practice is essential, and </span><span style="font-family:'Times New Roman'; font-size:11pt">Health </span><span style="font-family:'Times New Roman'; font-size:11pt">Department</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> work with the health care providers to drive up standards.  </span><span style="font-family:'Times New Roman'; font-size:11pt">I</span><span style="font-family:'Times New Roman'; font-size:11pt">t is important that safe, effective optimum methods of decontamination are used.  </span><span style="font-family:'Times New Roman'; font-size:11pt">In 2006 </span><span style="font-family:'Times New Roman'; font-size:11pt">NICE</span><span style="font-family:'Times New Roman'; font-size:11pt"> provided specific advice</span><span style="font-family:'Times New Roman'; font-size:11pt"> (attached as </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Annex</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> E</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt"> on </span><span style="font-family:'Times New Roman'; font-size:11pt">patient safety and reduction of risk of transmission of CJD via interventional procedures</span><a name="_ftnref1"></a><a href="#_ftn1">[1]</a><span style="font-family:'Times New Roman'; font-size:11pt"> in respect of neuro and ophthalmic surgery, which are associated with the greatest potential risk of human prion disease transmission via surgical instruments.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="25" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">There is </span><span style="font-family:'Times New Roman'; font-size:11pt">some limited </span><span style="font-family:'Times New Roman'; font-size:11pt">evidence from animal models of </span><span style="font-family:'Times New Roman'; font-size:11pt">the </span><span style="font-family:'Times New Roman'; font-size:11pt">potential </span><span style="font-family:'Times New Roman'; font-size:11pt">for </span><span style="font-family:'Times New Roman'; font-size:11pt">dental routes of transmission of infection.  In April 2007</span><span style="font-family:'Times New Roman'; font-size:11pt">, following peer reviewed research,</span><span style="font-family:'Times New Roman'; font-size:11pt"> the Chief Dental Officer advised all dentists in the UK to use only single-use endodontic (root canal) reamers and files, and to ensure that the highest standards of decontamination are observed for all dental instruments.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Current Issues</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Surveillance</span></p><ol start="26" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Surveillance is the cornerstone of the Government’s policy to monitor and control the spread of vCJD.  The incidence of all forms of CJD is monitored in the UK by the </span><span style="font-family:'Times New Roman'; font-size:11pt">CJDRSU</span><span style="font-family:'Times New Roman'; font-size:11pt">.  The Unit brings together a team of clinical neurologists, neuropathologists and scientists specialising in this group of conditions.  Whilst the number of clinical cases of vCJD has fallen (there ha</span><span style="font-family:'Times New Roman'; font-size:11pt">s been only one case since 2010</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> the potential for long incubation periods for these conditions and lack of knowledge about the implications of prevalence of sub-clinical infection (see below) means that </span><span style="font-family:'Times New Roman'; font-size:11pt">the need for specialist </span><span style="font-family:'Times New Roman'; font-size:11pt">surveillance will continue in the coming years.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="27" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">In addition</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">since the 1990s </span><span style="font-family:'Times New Roman'; font-size:11pt">the Department </span><span style="font-family:'Times New Roman'; font-size:11pt">has </span><span style="font-family:'Times New Roman'; font-size:11pt">fund</span><span style="font-family:'Times New Roman'; font-size:11pt">ed </span><span style="font-family:'Times New Roman'; font-size:11pt">specialist surveillance of transfusion histories via the </span><span style="font-family:'Times New Roman'; font-size:11pt">Transfusion medicine epidemiology review (TMER), </span><span style="font-family:'Times New Roman'; font-size:11pt">of </span><span style="font-family:'Times New Roman'; font-size:11pt">primary immunodeficiency patients exposed to UK sourced immunoglobulin</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> and of </span><span style="font-family:'Times New Roman'; font-size:11pt">Progressive Intellectual and Neurological Deterioration (PIND) in Children (including CJD).</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Prevalence of vCJD in the population</span></p><ol start="28" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">A major strand of the Department’s </span><span style="font-family:'Times New Roman'; font-size:11pt">currently </span><span style="font-family:'Times New Roman'; font-size:11pt">funded work on vCJD </span><span style="font-family:'Times New Roman'; font-size:11pt">is</span><span style="font-family:'Times New Roman'; font-size:11pt"> devoted to prevalence studies, to try and better understand the number of people who may be infected but show no symptoms, so that appropriate evidence based and cost effective risk management strategies can be developed.  Estimates of the number of people who may be incubating vCJD have been made based on modelling and vary widely.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="29" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The most recent prevalence study results are provided at </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Annex </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">F</span><span style="font-family:'Times New Roman'; font-size:11pt">, and </span><span style="font-family:'Times New Roman'; font-size:11pt">an</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">independent expert </span><span style="font-family:'Times New Roman'; font-size:11pt">ACDP statement </span><span style="font-family:'Times New Roman'; font-size:11pt">published in July 2012 </span><span style="font-family:'Times New Roman'; font-size:11pt">on the occurrence of vCJD and prevalence of infection in the UK population is at </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Annex </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">G</span><span style="font-family:'Times New Roman'; font-size:11pt">.  This study</span><span style="font-family:'Times New Roman'; font-size:11pt"> looks</span><span style="font-family:'Times New Roman'; font-size:11pt"> for the presence of abnormal prion protein in stored appendix tissue removed during surgery</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">tested </span><span style="font-family:'Times New Roman'; font-size:11pt">by immunohistochemistry (IHC – where thin tissue slices are stained by a variety of methods and individually studied under a microscope)</span><span style="font-family:'Times New Roman'; font-size:11pt">; it</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">reviewed </span><span style="font-family:'Times New Roman'; font-size:11pt">32,441 appendix samples, collected </span><span style="font-family:'Times New Roman'; font-size:11pt">during surgery since 2000 on patients born between 1941 and 1985.  Of these, 16 samples were judged to be “positive”</span><a name="_ftnref2"></a><a href="#_ftn2">[2]</a><span style="font-family:'Times New Roman'; font-size:11pt">.  This indicates a central prevalence estimate very close to 1 in 2,000 in the age cohort covered, with a 95% Confidence Interval running from approximately 1 in 3,500 to 1 in 1,250.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="30" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">ACDP </span><span style="font-family:'Times New Roman'; font-size:11pt">concluded that the survey “provides the most reliable available indication of the prevalence of asymptomatic vCJD infection within the UK population</span><span style="font-family:'Times New Roman'; font-size:11pt">”</span><a name="_ftnref3"></a><a href="#_ftn3">[3]</a><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="31" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">To better understand the meaning of results indicative of the presence of abnormal prion protein in 2013</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> the Department started funding a further study of stored appendix issues.  This study has two arms</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> one to test appendix samples archived before 1980 (prior to the BSE outbreak) and one to test samples from those born in 1996 or later</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> by which time measures had been put in place to protect the food chain.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="32" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">It should be noted that the development of clinical vCJD is influenced by genetic factors, in particular the position of the codon 129 of the prion gene.  On this codon individuals may have either of two amino-acids - methionine or valine.  This gives each individual three potential genotypes methionine/methionine (termed methionine homozygous, or MM), valine/valine (valine homozygous, or VV) or both (methionine-valine heterozygous, or MV).  So far all cases of clinical vCJD for which we have genetic information have been methionine homozygous (MM).  The prevalence studies of appendix material include analysis of the genotypes of any reactive samples.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">vCJD and b</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">lood</span></p><ol start="33" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">A blood test for vCJD may be advantageous for both health protection and possibly prevalence study purposes.  Unfortunately, there are current</span><span style="font-family:'Times New Roman'; font-size:11pt">ly</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">no </span><span style="font-family:'Times New Roman'; font-size:11pt">tests suitable for </span><span style="font-family:'Times New Roman'; font-size:11pt">such </span><span style="font-family:'Times New Roman'; font-size:11pt">use.  A joint meeting of the TSE Risk Assessment Sub-Group and the </span><span style="font-family:'Times New Roman'; font-size:11pt">UK </span><span style="font-family:'Times New Roman'; font-size:11pt">Blood Services Prion Working Group </span><span style="font-family:'Times New Roman'; font-size:11pt">(PWG) </span><span style="font-family:'Times New Roman'; font-size:11pt">took place</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">on 25 October 2012 </span><span style="font-family:'Times New Roman'; font-size:11pt">to review test developments</span><span style="font-family:'Times New Roman'; font-size:11pt">, and an independent review of all tests currently in development was published in 2013</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><a name="_ftnref4"></a><a href="#_ftn4">[4]</a></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="34" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The potential for a blood test was heightened in December 2003, when the then Secretary of State made a statement to Parliament on the first case of vCJD possibly acquired through transfusion of whole blood.  Following this</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> other transfusion recipients identified to be at increased risk were </span><span style="font-family:'Times New Roman'; font-size:11pt">notified.  This enabled</span><span style="font-family:'Times New Roman'; font-size:11pt"> public health precautions to be taken to reduce possible onward transm</span><span style="font-family:'Times New Roman'; font-size:11pt">issions.  Currently there are 16</span><span style="font-family:'Times New Roman'; font-size:11pt"> living patients identified to be at increased risk of vCJD as a result of receiving blood transfusion from donors who are known to have subsequently developed </span><span style="font-family:'Times New Roman'; font-size:11pt">clinical</span><span style="font-family:'Times New Roman'; font-size:11pt"> vCJD.  Four occurrences of possible transfusion associated transmission have now been identified: in three cases, the recipients developed clinical vCJD, in the other case the patient died of unrelated causes but evidence of abnormal prion was found at autopsy.</span></li></ol><p style="margin:0pt 0pt 0pt 18pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="35" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">In 2004</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> in light of the potential for blood transmissions, the Department commissioned an assessment</span><span style="font-family:'Times New Roman'; font-size:11pt"> by Det Norske Veritas </span><span style="font-family:'Times New Roman'; font-size:11pt">of the vCJD risks from blood products used to treat bleeding disorders such as haemophilia.  As a result, all people with haemophilia and blood disorders treated with UK derived products between 1980 and 2001 were designated ‘at risk for public health purposes’ in relation to vCJD.  Haemophilia patients are now provided, </span><span style="font-family:'Times New Roman'; font-size:11pt">wherever suitable, with a centrally funded synthetic product.</span></li></ol><p style="margin:0pt 0pt 0pt 18pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="36" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">In February 2009 the first finding of abnormal prion protein in a spleen tissue sample of a patient with haemophilia was announced.  This finding was made at autopsy in a spleen sample of a man in the 70-80 age group who had died of causes unrelated to vCJD or any other neurological disorder.  It is known that the patient had received product manufactured from a large pool known to have contained at least one donation from a person who later developed vCJD.  It is not possible to tell with any certainty where the abnormal prion protein originated and a risk assessment concluded that:</span></li></ol><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">t</span><span style="font-family:'Times New Roman'; font-size:11pt">he most likely cause of infection for this patient was from the factor VIII product used to treat haemophilia</span><span style="font-family:'Times New Roman'; font-size:11pt">;</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt"> it was more likely that the infection came from a product that was </span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">not</span><span style="font-family:'Times New Roman'; font-size:11pt"> made from a pool known to contain a donation from someone who later went on to die from vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> because of the large overall number of product units the patient had received.</span></li></ul><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="37" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The </span><span style="font-family:'Times New Roman'; font-size:11pt">potential for the use of a blood test for asymptomatic prion disease has been comprehensively considered by the Department</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">its agencies</span><span style="font-family:'Times New Roman'; font-size:11pt"> and advisory committees</span><span style="font-family:'Times New Roman'; font-size:11pt">.  </span><span style="font-family:'Times New Roman'; font-size:11pt">Reports and publications i</span><span style="font-family:'Times New Roman'; font-size:11pt">nclud</span><span style="font-family:'Times New Roman'; font-size:11pt">e a </span><span style="font-family:'Times New Roman'; font-size:11pt">Populus </span><span style="font-family:'Times New Roman'; font-size:11pt">qualitative </span><span style="font-family:'Times New Roman'; font-size:11pt">and </span><span style="font-family:'Times New Roman'; font-size:11pt">quantitative research report on </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Opinion Former Attitudes Towards The Possible Introduction Of A vCJD Test For Blood Donations</span><a name="_ftnref5"></a><a href="#_ftn5">[5]</a><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">, </span><span style="font-family:'Times New Roman'; font-size:11pt">and a</span><span style="font-family:'Times New Roman'; font-size:11pt"> report </span><span style="font-family:'Times New Roman'; font-size:11pt">that maps out the consequences of screening blood donations for PrP</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">Sc</span><a name="_ftnref6"></a><a href="#_ftn6">[6]</a><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="38" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">If a suitable test </span><span style="font-family:'Times New Roman'; font-size:11pt">is</span><span style="font-family:'Times New Roman'; font-size:11pt"> put forward </span><span style="font-family:'Times New Roman'; font-size:11pt">it</span><span style="font-family:'Times New Roman'; font-size:11pt"> would be considered by the UK blood services P</span><span style="font-family:'Times New Roman'; font-size:11pt">WG</span><span style="font-family:'Times New Roman'; font-size:11pt"> who advi</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt">e those services, and by the ACDP TSE Sub Group who advise </span><span style="font-family:'Times New Roman'; font-size:11pt">UK Health Departments</span><span style="font-family:'Times New Roman'; font-size:11pt">.  Taking into account the work of those groups</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">recommendations on the use or otherwise of a test would be considered by SaBTO and that group’s advice provided to Ministers.</span></li></ol><p style="margin:0pt 0pt 0pt 7.1pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="39" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">It </span><span style="font-family:'Times New Roman'; font-size:11pt">is </span><span style="font-family:'Times New Roman'; font-size:11pt">PWG’s responsibility to advise on </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">the requirements for evaluation of prion assays </span><span style="font-family:'Times New Roman'; font-size:11pt">and ACDP’s to advise on the management of TSE risks in order to reduce the risk of TSE transmission.  SaBTO has the specific role of</span><span style="font-family:'Times New Roman'; font-size:11pt"> advising Ministers of the UK Government and the Devolved</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Administrations on the most appropriate ways to ensure the safety of blood, including the introduction of new</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">safety measures</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="40" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">In 2011 with increasing </span><span style="font-family:'Times New Roman'; font-size:11pt">disparity between the observed and predicted cases of vCJD, and </span><span style="font-family:'Times New Roman'; font-size:11pt">significant developments in the understanding of infectivity and prevalence</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> the department commissioned a report to re-examine the scenarios for </span><span style="font-family:'Times New Roman'; font-size:11pt">b</span><span style="font-family:'Times New Roman'; font-size:11pt">lood-borne transmission of vCJD</span><a name="_ftnref7"></a><a href="#_ftn7">[7]</a><span style="font-family:'Times New Roman'; font-size:11pt">.  This report</span><span style="font-family:'Times New Roman'; font-size:11pt">’</span><span style="font-family:'Times New Roman'; font-size:11pt">s </span><span style="font-family:'Times New Roman'; font-size:11pt">main conclusions </span><span style="font-family:'Times New Roman'; font-size:11pt">were</span><span style="font-family:'Times New Roman'; font-size:11pt"> as follows.</span></li></ol><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:10pt; margin:0pt 0pt 0pt 27.6pt; padding-left:8.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Early findings from an ongoing survey of appendix tissues being conducted by the Health Protection Agency (HPA) confirm the previous estimates for the prevalence of prion infection within the population, and extend this finding to older age cohorts than those examined previously.</span></li><li style="font-family:Symbol; font-size:10pt; margin:0pt 0pt 0pt 27.6pt; padding-left:8.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Evidence now suggests a lower estimate for the level of infectivity in blood. </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">In the scenarios previously used, for example, a unit of red cells sourced from an infective donor prior to leucodepletion (removal of white blood cells, introduced in the UK in 1999) would have contained a large number (perhaps t</span><span style="font-family:'Times New Roman'; font-size:11pt">housands) of “Infective Doses”. </span><span style="font-family:'Times New Roman'; font-size:11pt"> The evidence now available suggests that a unit contains of the order of one “Infective Dose”.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt"> The risk of transmission from an individual donor to</span><span style="font-family:'Times New Roman'; font-size:11pt"> a</span><span style="font-family:'Times New Roman'; font-size:11pt"> recipient could remain substantial, but would not occur in every case.</span></li><li style="font-family:Symbol; font-size:10pt; margin:0pt 0pt 0pt 27.6pt; padding-left:8.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">It is now appropriate to calibrate transmission models against observed clinical case numbers, subject to taking a precautionary approach in estimating how many vCJD infections would have shown up as clinical cases, as well as how many known cases might have been due to blood-borne infection</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="41" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The Department continues to keep the findings of ongoing prevalence studies under close review, and ACDP and SaBTO </span><span style="font-family:'Times New Roman'; font-size:11pt">currently </span><span style="font-family:'Times New Roman'; font-size:11pt">use th</span><span style="font-family:'Times New Roman'; font-size:11pt">e</span><span style="font-family:'Times New Roman'; font-size:11pt"> outcomes of this report when considering </span><span style="font-family:'Times New Roman'; font-size:11pt">potential </span><span style="font-family:'Times New Roman'; font-size:11pt">risk management actions.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="42" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">One potential method of reducing the blood transmission risk </span><span style="font-family:'Times New Roman'; font-size:11pt">is the use of </span><span style="font-family:'Times New Roman'; font-size:11pt">prion filters which aim to remove potential infectivity from donated blood.  </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO</span><span style="font-family:'Times New Roman'; font-size:11pt"> reviewed evidence of prion filter efficacy at a meeting in December 2012</span><a name="_ftnref8"></a><a href="#_ftn8">[8]</a><span style="font-family:'Times New Roman'; font-size:11pt">, and they did not recommend the use of the prion filter technology assessed.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Decontamination of </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">surgical and d</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">ental instruments</span></p><ol start="43" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">A</span><span style="font-family:'Times New Roman'; font-size:11pt">CDP has provided advice on the handling of instruments and devices in procedures on patients with known or suspected CJD/vCJD.  Specific guidance is provided by </span><span style="font-family:'Times New Roman'; font-size:11pt">NICE</span><span style="font-family:'Times New Roman'; font-size:11pt"> for neuro and ophthalmology surgery</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> and</span><span style="font-family:'Times New Roman'; font-size:11pt"> by</span><span style="font-family:'Times New Roman'; font-size:11pt"> the Chief Dental Officer on single-use endodontic (root canal) reamers and files.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="44" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">In addition t</span><span style="font-family:'Times New Roman'; font-size:11pt">he Code of Practice for health and adult social care on the prevention and control of infections and related guidance requires providers of healthcare to have a policy on decontamination of reusable medical devices and thus ensures that decontamination is part of the infection prevention and control programme.  Management systems should be in place to ensure adequate supplies of instruments and to minimise the risk of transmission of infection to patients and staff.  For example</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> endoscopes and surgical instruments are required to be individually identifiable, or identified to a set of which they are a consistent member, throughout the use and decontamination cycle in order to ensure subsequent traceability.  Systems should also be implemented to enable the identification of service users on whom the medical devices have been used.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="45" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The Department’s current guidance for healthcare providers on the management and decontamination of surgical instruments</span><span style="font-family:'Times New Roman'; font-size:11pt">, which</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">takes account of the latest evidence</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">is contained in</span><span style="font-family:'Times New Roman'; font-size:11pt"> the 2013 publication</span><span style="font-family:'Times New Roman'; font-size:11pt"> ‘Choice Framework for local Policy and Procedures (CFPP) 01-01 – Management and decontamination of surgical instruments (medical devices) used in acute care’</span><a name="_ftnref9"></a><a href="#_ftn9">[9]</a><span style="font-family:'Times New Roman'; font-size:11pt">. CFPP 01-01 Part A: The formulation of local policies and choices contains specific sections relating to </span><span style="font-family:'Times New Roman'; font-size:11pt">transmissible spongiform encephalopathies</span><span style="font-family:'Times New Roman'; font-size:11pt"> (TSEs) including CJD and vCJD. Section 5 in Part A incorporates a section on the evidence base entitled ‘The evidence base: the risk from prion diseases and findings from the National Decontamination Survey’.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="46" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">With CFPP 01-01, the DH is providing guidance which supports:</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">• the prevention and control of the risk of transmission of infection through surgical instruments – with specific reference to the theoretical risk of human prion diseases transmission (TSEs);</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">• a comprehensive approach to risk control and reduction across instrument management and decontamination;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">• assurance over the management of surgical instruments, in terms of availability, quality and</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">suitability;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">• the preservation and advance of high-quality engineering through the support of European Norms (ENs), quality systems and standards;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">• guidance for optimisation of the environment, equipment and facilities used in surgical decontamination.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="47" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">CFPP 01-01 refers to </span><span style="font-family:'Times New Roman'; font-size:11pt">the </span><span style="font-family:'Times New Roman'; font-size:11pt">2006 </span><span style="font-family:'Times New Roman'; font-size:11pt">NICE </span><span style="font-family:'Times New Roman'; font-size:11pt">guidance </span><span style="font-family:'Times New Roman'; font-size:11pt">and guidance derived from the </span><span style="font-family:'Times New Roman'; font-size:11pt">ACDP</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">TSE</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">S</span><span style="font-family:'Times New Roman'; font-size:11pt">ub</span><span style="font-family:'Times New Roman'; font-size:11pt"> Group </span><span style="font-family:'Times New Roman'; font-size:11pt">throughout. It draws on the findings of the National Decontamination Survey (NDS) (2008– 2010) for high risk surgical procedures, to highlight aspects of decontamination management practice that need addressing, and presents findings from NDS pilot studies to </span><span style="font-family:'Times New Roman'; font-size:11pt">suggest ways in which decontamination manage</span><span style="font-family:'Times New Roman'; font-size:11pt">ment practices can be developed.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="48" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The Department also provides guidance on the decontamination of flexible endoscopes via its </span><span style="font-family:'Times New Roman'; font-size:11pt">publication,</span><span style="font-family:'Times New Roman'; font-size:11pt"> CFPP 01-06: Decontamination of flexible endoscopes, and</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">decontamination in primary care dental practices via </span><span style="font-family:'Times New Roman'; font-size:11pt">Health Technical Memorandum (HTM) 01-05: </span><span style="font-family:'Times New Roman'; font-size:11pt">Decontamination in primary care dental practices. These guidance publications also contain guidance and references relating to CJD and vCJD in context of the subject matter covered.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="49" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">As evidence grows, individual reports and findings from commissioned research </span><span style="font-family:'Times New Roman'; font-size:11pt">will</span><span style="font-family:'Times New Roman'; font-size:11pt"> be incorporated into CFPP 01-01, CFPP 01-06 and HTM 01-05 and the updated guidance provided via the Department’s portal on GOV.UK</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="50" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">CFPP and HTM guidance is attached as </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Annex</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> I</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="51" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">As announced in the House of Commons </span><span style="font-family:'Times New Roman'; font-size:11pt">on 28 April 2011</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> the Department has committed £2.4 million to </span><span style="font-family:'Times New Roman'; font-size:11pt">on-going</span><span style="font-family:'Times New Roman'; font-size:11pt"> research related to decontamination science.  When completed</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> the results of these studies will be considered by the Department’s scientific advisory committees and guidance, such as that contained in the CFPP</span><span style="font-family:'Times New Roman'; font-size:11pt">, will be revised as necessary.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="52" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Additionally in 2004 the Department</span><span style="font-family:'Times New Roman'; font-size:11pt"> established within the Health P</span><span style="font-family:'Times New Roman'; font-size:11pt">rotection Agency, now Public Health England, the Rapid Review Panel (RRP).  The RRP provides a prompt assessment of new and novel equipment, materials, and other products or protocols that may be of value to the NHS in improving hospital infection control and reducing hospital acquired infections.  </span><span style="font-family:'Times New Roman'; font-size:11pt">It is </span><span style="font-family:'Times New Roman'; font-size:11pt">not</span><span style="font-family:'Times New Roman'; font-size:11pt"> within RRP’s remit to clinically evaluate or undertake the evaluation of products within the NHS, which is for manufacturers to initiate and complete. Neither is it for the Panel nor the Department to influence procurement and the "uptake" of products into the NHS once recommendations are formulated.</span></li></ol><p style="margin:0pt 0pt 0pt 18pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="53" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The </span><span style="font-family:'Times New Roman'; font-size:11pt">RRP’s</span><span style="font-family:'Times New Roman'; font-size:11pt"> remit includes products which claim anti-prion </span><span style="font-family:'Times New Roman'; font-size:11pt">effectiveness, and additional details of </span><span style="font-family:'Times New Roman'; font-size:11pt">its</span><span style="font-family:'Times New Roman'; font-size:11pt"> work, particularly with relevance to anti-prion products</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> will be found in Public Health England’s response </span><span style="font-family:'Times New Roman'; font-size:11pt">to </span><span style="font-family:'Times New Roman'; font-size:11pt">the Inquiry</span><span style="font-family:'Times New Roman'; font-size:11pt">, as they provide the secretariat for this independent advisory committee.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Treatment for vCJD</span></p><ol start="54" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">The </span><span style="font-family:'Times New Roman'; font-size:11pt">Department</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">funded the National Prion Clinic </span><span style="font-family:'Times New Roman'; font-size:11pt">(now at UCLH, formerly Imperial)</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">with </span><span style="font-family:'Times New Roman'; font-size:11pt">over </span><span style="font-family:'Times New Roman'; font-size:11pt">£</span><span style="font-family:'Times New Roman'; font-size:11pt">7</span><span style="font-family:'Times New Roman'; font-size:11pt"> million for a study in collaboration with </span><span style="font-family:'Times New Roman'; font-size:11pt">an industry partner </span><span style="font-family:'Times New Roman'; font-size:11pt">into </span><span style="font-family:'Times New Roman'; font-size:11pt">the </span><span style="font-family:'Times New Roman'; font-size:11pt">potential </span><span style="font-family:'Times New Roman'; font-size:11pt">for </span><span style="font-family:'Times New Roman'; font-size:11pt">the </span><span style="font-family:'Times New Roman'; font-size:11pt">development of an effective treatment for prion infection of humans.  This funding was in place from February 2006 until June 2013.</span></li></ol><p style="margin:0pt 0pt 0pt 18pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="55" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">T</span><span style="font-family:'Times New Roman'; font-size:11pt">here </span><span style="font-family:'Times New Roman'; font-size:11pt">remain </span><span style="font-family:'Times New Roman'; font-size:11pt">no effective treatments for vCJD.  The only therapeutic agent recently used was Pentosan, which whilst permitting the survival of some vCJD patients for over 6 years provided limited, if any, therapeutic benefit.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Government expert a</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">dvice on TSEs</span></p><ol start="56" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">After a review of Government </span><span style="font-family:'Times New Roman'; font-size:11pt">Arm’s Length</span><span style="font-family:'Times New Roman'; font-size:11pt"> Bod</span><span style="font-family:'Times New Roman'; font-size:11pt">i</span><span style="font-family:'Times New Roman'; font-size:11pt">es in 2010</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">SEAC, which was set up in 1990, </span><span style="font-family:'Times New Roman'; font-size:11pt">was </span><span style="font-family:'Times New Roman'; font-size:11pt">dissolved in </span><span style="font-family:'Times New Roman'; font-size:11pt">March 2011</span><span style="font-family:'Times New Roman'; font-size:11pt">.  ACDP established a TSE Risk Assessment Sub</span><span style="font-family:'Times New Roman'; font-size:11pt">-</span><span style="font-family:'Times New Roman'; font-size:11pt">Group to take forward SEAC’s role.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="57" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">With the changing NHS structures, t</span><span style="font-family:'Times New Roman'; font-size:11pt">he CJD Incidents Panel, which </span><span style="font-family:'Times New Roman'; font-size:11pt">had since 2001 </span><span style="font-family:'Times New Roman'; font-size:11pt">provide</span><span style="font-family:'Times New Roman'; font-size:11pt">d </span><span style="font-family:'Times New Roman'; font-size:11pt">operational advice on local actions </span><span style="font-family:'Times New Roman'; font-size:11pt">from the centre</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">was wound up in March 2013.</span><span style="font-family:'Times New Roman'; font-size:11pt">  Responsibility for actions on individual CJD incidents are now managed at the local level, in the same way as all other incidents related to patient</span><span style="font-family:'Times New Roman'; font-size:11pt">-</span><span style="font-family:'Times New Roman'; font-size:11pt">to</span><span style="font-family:'Times New Roman'; font-size:11pt">-</span><span style="font-family:'Times New Roman'; font-size:11pt">patient risks.  Local teams now apply guidance on handling such incidents published by the Incidents Panel and ACDP.  The vast majority of CJD related incidents involve sporadic or familial CJD.  After abolition of the Panel, local incident teams are able to refer novel issues to the ACDP where necessary.  Local teams are asked to let Public Health England know when a CJD patient notification has been made to enable any appropriate enhanced surveillance of those so notified.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="58" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">From April 2013 ACDP’s </span><span style="font-family:'Times New Roman'; font-size:11pt">TSE Risk Management Sub-Group </span><span style="font-family:'Times New Roman'; font-size:11pt">took </span><span style="font-family:'Times New Roman'; font-size:11pt">on all the "generic" TSE risk management functions </span><span style="font-family:'Times New Roman'; font-size:11pt">until then </span><span style="font-family:'Times New Roman'; font-size:11pt">performed by th</span><span style="font-family:'Times New Roman'; font-size:11pt">at</span><span style="font-family:'Times New Roman'; font-size:11pt"> Sub Group and the Incidents Panel.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="59" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">T</span><span style="font-family:'Times New Roman'; font-size:11pt">he Government continues to be advised on CJD and other TSEs by the </span><span style="font-family:'Times New Roman'; font-size:11pt">ACDP</span><span style="font-family:'Times New Roman'; font-size:11pt">, now largely through a single </span><span style="font-family:'Times New Roman'; font-size:11pt">ACDP TSE Sub</span><span style="font-family:'Times New Roman'; font-size:11pt">-</span><span style="font-family:'Times New Roman'; font-size:11pt">Group (which combines the expertise and remits of the previous TE Risk Management and Risk Assessment Sub</span><span style="font-family:'Times New Roman'; font-size:11pt">-</span><span style="font-family:'Times New Roman'; font-size:11pt">Groups)</span><span style="font-family:'Times New Roman'; font-size:11pt">, which provides advice on all matters related to TSE risk assessment and management</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="60" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">T</span><span style="font-family:'Times New Roman'; font-size:11pt">he Department </span><span style="font-family:'Times New Roman'; font-size:11pt">is also advised by </span><span style="font-family:'Times New Roman'; font-size:11pt">specialists on SaBTO in relation to prion transmission risk reduction measures within their remit.</span></li></ol><p style="margin:0pt 0pt 0pt 18pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="61" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Additionally the Department funds (and attends as an observer) the CJD Oversight Committee, which provides support and access to rare and specific samples to those developing potential CJD tests.  The Department also </span><span style="font-family:'Times New Roman'; font-size:11pt">attends</span><span style="font-family:'Times New Roman'; font-size:11pt"> the </span><span style="font-family:'Times New Roman'; font-size:11pt">PWG,</span><span style="font-family:'Times New Roman'; font-size:11pt"> which advises the four UK blood services on issues related to prion risk reduction measures including potential tests.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Future</span><a name="SAQ049"></a><a name="SAQ050"></a><a name="SAQ056"></a><a name="SAQ057"></a><a name="SAQ058"></a><a name="SAQ061"></a><a name="SAQ062"></a><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> i</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">ssues</span></p><ol start="62" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">W</span><span style="font-family:'Times New Roman'; font-size:11pt">e cannot be sure that the number of vCJD cases is tailing off, especially because of the potential length of the disease incubation period, which may be several decades, and other scientific uncertainties still surrounding the behaviour of the causative prion agent (such as the nature and pattern of infectivity, and the influence of genotype variations in the population).  BSE and vCJD will continue to be of concern to health professionals and the public fo</span><span style="font-family:'Times New Roman'; font-size:11pt">r the foreseeable future.</span></li></ol><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="63" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 25.1pt; orphans:0; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Over the next </span><span style="font-family:'Times New Roman'; font-size:11pt">2</span><span style="font-family:'Times New Roman'; font-size:11pt">-</span><span style="font-family:'Times New Roman'; font-size:11pt">3 years</span><span style="font-family:'Times New Roman'; font-size:11pt">, the</span><span style="font-family:'Times New Roman'; font-size:11pt"> Department regards the </span><span style="font-family:'Times New Roman'; font-size:11pt">key CJD issues </span><span style="font-family:'Times New Roman'; font-size:11pt">as</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">the need to maintain investment in CJD surveillance and research because of the long-term uncertainties;</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">ensuring a balance is maintained in the cost/benefit of additional risk reduction measures including the potential use of additional safety precautions;</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">at the conclusion of the current research studies, review and as necessary </span><span style="font-family:'Times New Roman'; font-size:11pt">revis</span><span style="font-family:'Times New Roman'; font-size:11pt">ion of</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">existing </span><span style="font-family:'Times New Roman'; font-size:11pt">advice on decontamination science and technologies</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> to ensure optimum levels of prion removal from instruments;</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">appropriate definition and handling of </span><span style="font-family:'Times New Roman'; font-size:11pt">individuals </span><span style="font-family:'Times New Roman'; font-size:11pt">defined as “at increased risk”, </span><span style="font-family:'Times New Roman'; font-size:11pt">to ensure </span><span style="font-family:'Times New Roman'; font-size:11pt">precautionary actions are measured and proportionate;</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">maintaining public health input to </span><span style="font-family:'Times New Roman'; font-size:11pt">Defra and </span><span style="font-family:'Times New Roman'; font-size:11pt">Food Standards Agency</span><span style="font-family:'Times New Roman'; font-size:11pt"> processes and assurance controls which impact on TSEs; and</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; orphans:0; padding-left:7.94pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">updating prevalence </span><span style="font-family:'Times New Roman'; font-size:11pt">information </span><span style="font-family:'Times New Roman'; font-size:11pt">as results from current studies accumulate, and </span><span style="font-family:'Times New Roman'; font-size:11pt">taking </span><span style="font-family:'Times New Roman'; font-size:11pt">account of results review strategies as appropriate.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">R</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">esponses to the particular questions posed by the committee</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Are UK policies governing who can donate blood and blood products, tissues and orga</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">ns sufficiently evidence-based?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Yes.  The policies on donor deferral are set within the requirements of the Blood Safety and Quality Regulations 2005</span><span style="font-family:'Times New Roman'; font-size:11pt">, which derive from </span><span style="font-family:'Times New Roman'; font-size:11pt">EU </span><span style="font-family:'Times New Roman'; font-size:11pt">Directive 2002/98/EC and associated Directives 2004/33/EC, 2005/61/EC and 2005/62/EC</span><span style="font-family:'Times New Roman'; font-size:11pt">, f</span><span style="font-family:'Times New Roman'; font-size:11pt">or which the </span><span style="font-family:'Times New Roman'; font-size:11pt">Medicines and Healthcare products Regulatory Agency (MHRA) is the Regulator </span><span style="font-family:'Times New Roman'; font-size:11pt">(see </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Annex </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">J </span><span style="font-family:'Times New Roman'; font-size:11pt">for further details of the MHRA’s role).  </span><span style="font-family:'Times New Roman'; font-size:11pt">The </span><span style="font-family:'Times New Roman'; font-size:11pt">requirements of the </span><span style="font-family:'Times New Roman'; font-size:11pt">2005 </span><span style="font-family:'Times New Roman'; font-size:11pt">Regulations </span><span style="font-family:'Times New Roman'; font-size:11pt">are </span><span style="font-family:'Times New Roman'; font-size:11pt">set </span><span style="font-family:'Times New Roman'; font-size:11pt">out </span><span style="font-family:'Times New Roman'; font-size:11pt">in the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:normal">Guidelines for the Blood Transfusion Services in the UK</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> (the current edition is the 8</span><span style="font-family:'Times New Roman'; font-size:7.33pt; font-weight:normal; vertical-align:super">th</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> published by TSO in March 2013),</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> available at:</span></li></ol><p style="margin:0pt 0pt 0pt 90pt; text-align:justify"><a href="http://www.transfusionguidelines.org.uk/Index.aspx?Publication=RB&amp;Section=25&amp;pageid=7905"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.transfusionguidelines.org.uk/Index.aspx?Publication=RB&amp;Section=25&amp;pageid=7905</span></a></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Chapter 3 of the</span><span style="font-family:'Times New Roman'; font-size:11pt">se</span><span style="font-family:'Times New Roman'; font-size:11pt"> guidelines covers “</span><a href="http://www.transfusionguidelines.org.uk/index.aspx?Publication=RB&amp;Section=25&amp;pageid=7911"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">Care and selection of whole blood and component donors (including donors of pre-deposit autologous blood)</span></a><span style="font-family:'Times New Roman'; font-size:11pt">“.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To reflect new evidence the </span><span style="font-family:'Times New Roman'; font-size:11pt">guidelines </span><span style="font-family:'Times New Roman'; font-size:11pt">are updated by </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Change Notifications</span><span style="font-family:'Times New Roman'; font-size:11pt"> (see: </span><a href="http://www.transfusionguidelines.org.uk/index.aspx?Publication=DL&amp;Section=12&amp;pageid=394"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.transfusionguidelines.org.uk/index.aspx?Publication=DL&amp;Section=12&amp;pageid=394</span></a><span style="font-family:'Times New Roman'; font-size:11pt">).</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">For tissue and organs, EU Directives 2004/23/EC, 2006/17/EC 2006/86, 2010/53/EU and 2012/25/EU set out standards of safety and quality for the procurement and transplantation of organs, tissue and cells. These have been implemented in the UK. In addition, </span><span style="font-family:'Times New Roman'; font-size:11pt">in 2011</span><span style="font-family:'Times New Roman'; font-size:11pt">SABTO issued</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Guidance on the Microbiological Safety of Human Organs, Tissues and Cells used in Transplantation</span><span style="font-family:'Times New Roman'; font-size:11pt">. This guidance updates and replaces the document issued in 2000 by the Advisory Committee on the Microbiological Safety of Blood Tissues and Organs for Transplantation. It provides advice on reducing to a minimum the avoidable transmission of infection through transplantation. </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Chapter 9 covers guidance on prions. The advice is attached at </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Annex</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">K</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Is NHS Blood and Transplant overly restrictive about who can donate, or should greater precautions be taken to further reduce risk?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">No, NHS Blood and Transplant base their practices on the 2005 Regulations set within the context of EU standards of quality and safety.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Evidence on updating the Guidelines come </span><span style="font-family:'Times New Roman'; font-size:11pt">from a </span><span style="font-family:'Times New Roman'; font-size:11pt">variety of sources, including SaBTO</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span></li></ol><p style="margin:0pt 0pt 0pt 90pt; text-align:justify"><a href="https://www.gov.uk/government/policy-advisory-groups/advisory-committee-on-the-safety-of-blood-tissues-and-organs"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/policy-advisory-groups/advisory-committee-on-the-safety-of-blood-tissues-and-organs</span></a></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="7" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO is the independent scientific committee that advises UK ministers and health departments on the most appropriate ways to ensure the safety of blood, cells, tissues and organs for transfusion/transplantation.  For example in 2011 SaBTO advised on a change in donor deferral policy in relation to m</span><span style="font-family:'Times New Roman'; font-size:11pt">en who have sex with men (MSM).</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Is the Government and its scientific advisory structure sufficiently responsive to the threat posed by emerging diseases being transmitted through blood and blood products, tissues and organs?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="8" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Yes.  The Committee has an effective independent scientific advisory committee structure including SaBTO and the ACDP (</span><a href="http://www.hse.gov.uk/aboutus/meetings/committees/acdp/index.htm"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.hse.gov.uk/aboutus/meetings/committees/acdp/index.htm</span></a><span style="font-family:'Times New Roman'; font-size:11pt">) and ACDP’s </span><span style="font-family:'Times New Roman'; font-size:11pt">TSE</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Sub Group (</span><a href="https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group</span></a><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt"> which publishes comprehensive guidance on reducing the risks of </span><span style="font-family:'Times New Roman'; font-size:11pt">CJD </span><span style="font-family:'Times New Roman'; font-size:11pt">in healthcare settings.  ACDP’s guidance is regularly reviewed and updated when new evidence based and cost effective risk reduction measures are presented.</span></li></ol><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="9" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In relation to their current enquiry the Select Committee will wish to rev</span><span style="font-family:'Times New Roman'; font-size:11pt">iew the </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO an</span><span style="font-family:'Times New Roman'; font-size:11pt">d ACDP reports and publications included or referenced in this evidence.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Has the threat of </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">on-going</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> transmission of vCJD through the blood and blood product supply been adequately mitigated?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="10" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Yes.  Measures to reduce the potential for secondary transmission of v</span><span style="font-family:'Times New Roman'; font-size:11pt">CJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> by blood have been successively introduced since the late 1990s.  A list of measures is available on SaBTO’s website at:</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/268288/vCJD_risk_reduction_measures_summary_Dec_2013_v1.1.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/268288/vCJD_risk_reduction_measures_summary_Dec_2013_v1.1.pdf</span></a></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="11" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To monitor evidence of potential blood related CJD transmissions the Department funds the TMER, a collaborative project between the UK </span><span style="font-family:'Times New Roman'; font-size:11pt">CJDRSU</span><span style="font-family:'Times New Roman'; font-size:11pt"> and the UK Blood Services.  TME</span><span style="font-family:'Times New Roman'; font-size:11pt">R</span><span style="font-family:'Times New Roman'; font-size:11pt">'s main purpose is to investigate whether there is any evidence that CJD or vCJD may have been transmitted via the blood supply. The TMER website containing the data collected and results of their investigations is at:</span></li></ol><p style="margin:0pt 0pt 0pt 108pt; text-align:justify"><a href="http://www.cjd.ed.ac.uk/TMER/TMER.htm"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.cjd.ed.ac.uk/TMER/TMER.htm</span></a></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">What are the strengths and weaknesses of NHS Blood and Transplant’s strategy, “Taking </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Organ Transplantation to 2020”?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="12" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There are currently around 8000 people in the UK actively waiting for an organ transplant – mostly kidney. This figure changes constantly as people join and leave the transplant waiting list. Because of the shortage of donated organs, around three people die every day waiting for a transplant</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">One organ donor can save or transform many lives (kidneys, lungs, liver, heart, pancreas small bowel) and many more can be helped through the donation of tissues (eg skin, tendons, bone, corneas). Between 2008 </span><span style="font-family:'Times New Roman'; font-size:11pt">and</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2013,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">based on recommendations made by the Organ Donation Taskforce, additional funding allowed a strengthening of the donation infrastructure. This included an increase in specialist nurses for organ donation and the establishment of Clinical Leads and Donation Committees in acute trusts to champion donation at a local level. This has seen organ donation from deceased donors increase by 60% to September 2013</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">compared to a 2007/08 baseline</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> and encouragingly donor rates continue to rise.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="13" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In 2010 it was estimated that the </span><span style="font-family:'Times New Roman'; font-size:11pt">UK transplant programme realised annual gross savings of around £316 million per annum to the NHS compared to other procedures such as dialysis. These savings will increase as transplant rates increase</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="14" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">However, over 40% of families refuse organ donation when asked</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and fewer than 5,000 people of the half a million who die every year, die in circumstances where they can donate their organs. Therefore it is vital to optimise the potential for donation in all cases.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="15" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In </span><span style="font-family:'Times New Roman'; font-size:11pt">July 2013 a</span><span style="font-family:'Times New Roman'; font-size:11pt"> new seven year UK-wide organ donation and transplantation strategy was published by NHS Blood and Transplant. The strategy builds on the last five years successful increase in donation. The aim is to make the UK match world class performance in organ donation and transplantation in the top performing countries. This will be done by reducing refusal rates from the current 40% to 20% (meaning 450 more donors and 1200 more transplants each year), a deceased donor rate of 26 per million population (currently </span><span style="font-family:'Times New Roman'; font-size:11pt">19 pmp) and a deceased donor transplant rate of 74 pmp (currently 49 pmp). A UK-wide oversight group has been established to oversee implementation.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="16" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Action </span><span style="font-family:'Times New Roman'; font-size:11pt">will focus in four key areas:</span></li></ol><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">I</span><span style="font-family:'Times New Roman'; font-size:11pt">ncreasing consent rates by making organ donation a usual part of end of life care where possible</span><span style="font-family:'Times New Roman'; font-size:11pt">;</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">E</span><span style="font-family:'Times New Roman'; font-size:11pt">ncouraging people an</span><span style="font-family:'Times New Roman'; font-size:11pt">d families to support donation;</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">O</span><span style="font-family:'Times New Roman'; font-size:11pt">ptimising donation in hospitals by identifying and referring all potential donors; </span><span style="font-family:'Times New Roman'; font-size:11pt">and</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">O</span><span style="font-family:'Times New Roman'; font-size:11pt">ptimising transplantation – more organs are useable with surgeons given more information and guidance to help them decide which organs can be s</span><span style="font-family:'Times New Roman'; font-size:11pt">afely transplanted and to whom.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">What further changes could be made to safely increase the supply of blood and blood products, tissues and organs?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="17" type="1" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; border-bottom-color:#e5e5e5; border-bottom-style:solid; border-bottom-width:0.75pt; font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; padding-bottom:8pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The UK’s blood, tissues and organs services </span><span style="font-family:'Times New Roman'; font-size:11pt">tak</span><span style="font-family:'Times New Roman'; font-size:11pt">e </span><span style="font-family:'Times New Roman'; font-size:11pt">a</span><span style="font-family:'Times New Roman'; font-size:11pt"> range of me</span><span style="font-family:'Times New Roman'; font-size:11pt">asures to maintain and increase, where appropriate, </span><span style="font-family:'Times New Roman'; font-size:11pt">donation</span><span style="font-family:'Times New Roman'; font-size:11pt">, and a number of procedures are in place to monitor </span><span style="font-family:'Times New Roman'; font-size:11pt">donation</span><span style="font-family:'Times New Roman'; font-size:11pt"> safety.  These include</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">testing </span><span style="font-family:'Times New Roman'; font-size:11pt">blood </span><span style="font-family:'Times New Roman'; font-size:11pt">donations for </span><span style="font-family:'Times New Roman'; font-size:11pt">key infections (see paragraph 20)</span><span style="font-family:'Times New Roman'; font-size:11pt">. The safety of blood transfusion is </span><span style="font-family:'Times New Roman'; font-size:11pt">monitored</span><span style="font-family:'Times New Roman'; font-size:11pt"> by Serious Hazards of Transfusion (SHOT)</span><span style="font-family:'Times New Roman'; font-size:11pt">, the UK’</span><span style="font-family:'Times New Roman'; font-size:11pt">s independent, professionally-</span><span style="font-family:'Times New Roman'; font-size:11pt">led haemovigilance scheme. It started in 1996 and was the first such scheme in the world. </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">SHOT collects and analyses anonymised information on adverse events and reactions in blood transfusion from all healthcare organisations. Where risks and problems are identified, SHOT produces recommendations to improve patient safety. The recommendations are put into </span><span style="font-family:'Times New Roman'; font-size:11pt">the SHOT </span><span style="font-family:'Times New Roman'; font-size:11pt">annual report</span><a name="_ftnref10"></a><a href="#_ftn10">[10]</a><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">circulated to</span><span style="font-family:'Times New Roman'; font-size:11pt">, amongst others, </span><span style="font-family:'Times New Roman'; font-size:11pt">the four UK Blood Services</span><span style="font-family:'Times New Roman'; font-size:11pt"> and</span><span style="font-family:'Times New Roman'; font-size:11pt"> the </span><span style="font-family:'Times New Roman'; font-size:11pt">four UK Health </span><span style="font-family:'Times New Roman'; font-size:11pt">Departments</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">For </span><span style="font-family:'Times New Roman'; font-size:11pt">tissues and organs</span><span style="font-family:'Times New Roman'; font-size:11pt">, a</span><span style="font-family:'Times New Roman'; font-size:11pt"> range of measures such as evidence-based risk assessment guidance, peer review and comparative data support surgeons to assess the risk/benefit of using a </span><span style="font-family:'Times New Roman'; font-size:11pt">particular organ.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">What lessons could be learnt from the screening and donation practices of other countries?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="19" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Within the EU the same requirements deriving from Directive </span><span style="font-family:'Times New Roman'; font-size:11pt">2002/98/EC </span><span style="font-family:'Times New Roman'; font-size:11pt">apply.  Individual countries work within the directive requirements according to local conditions with </span><span style="font-family:'Times New Roman'; font-size:11pt">regard</span><span style="font-family:'Times New Roman'; font-size:11pt"> to the prevalence and incidence of potentially blood borne infections.  For example whilst some countries test all blood donations for West Nile Virus (WNV) because it circulates in that country, the UK test</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> only donors returning recently from travel to such areas.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="20" type="1" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The application of screening and donation practices varies widely and the UK has a </span><span style="font-family:'Times New Roman'; font-size:11pt">well-established</span><span style="font-family:'Times New Roman'; font-size:11pt"> system for </span><span style="font-family:'Times New Roman'; font-size:11pt">blood donation screening using evidence based tests.  All blood </span><span style="font-family:'Times New Roman'; font-size:11pt">donations are tested on every occasion for evidence of infection with:</span></li><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Huma</span><span style="font-family:'Times New Roman'; font-size:11pt">n Immunodeficiency Virus (HIV),</span></li><li style="background-color:#ffffff; font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">hepatitis B virus (HBV),</span></li><li style="background-color:#ffffff; font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">hepatitis C virus (HCV),</span></li><li style="background-color:#ffffff; font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Human T-cell</span><span style="font-family:'Times New Roman'; font-size:11pt"> Lymphotropic Virus (HTLV), and</span></li><li style="background-color:#ffffff; font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">syphilis.</span></li></ul></ol><p style="background-color:#ffffff; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="background-color:#ffffff; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Sensitive tests are used which have been assessed as suitable for screening blood donors.  In addition, donors who may </span><span style="font-family:'Times New Roman'; font-size:11pt">have </span><span style="font-family:'Times New Roman'; font-size:11pt">been exposed to certain infections found outside the UK, but which are transmissible by blood transfusion (malaria and Chagas' disease)</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> undergo </span><span style="font-family:'Times New Roman'; font-size:11pt">specific testing before their blood is released for use.  Tests for Cytomegalovirus (CMV) are also carried out on a number of donations to meet the specific clinical needs </span><span style="font-family:'Times New Roman'; font-size:11pt">of </span><span style="font-family:'Times New Roman'; font-size:11pt">patients with depressed immunity.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="21" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">W</span><span style="font-family:'Times New Roman'; font-size:11pt">ith regard</span><span style="font-family:'Times New Roman'; font-size:11pt"> to</span><span style="font-family:'Times New Roman'; font-size:11pt"> vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> no other country has introduced the number of measures currently performed in the UK.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">January 2014</span><br style="page-break-before:always; clear:both" /></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ANNEXES</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ANNEX A</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Creutzfeldt-Jakob disease in the UK (by calendar year)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ANNEX B</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Graph of UK vCJD cases 1994-2013</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ANNEX C</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO - Measures </span><span style="font-family:'Times New Roman'; font-size:11pt">currently in place in the UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">to</span><span style="font-family:'Times New Roman'; font-size:11pt"> reduce the potential risk of transmittin</span><span style="font-family:'Times New Roman'; font-size:11pt">g </span><span style="font-family:'Times New Roman'; font-size:11pt">variant </span><span style="font-family:'Times New Roman'; font-size:11pt">Creutzfeldt-Jakob </span><span style="font-family:'Times New Roman'; font-size:11pt">disease via blood</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ANNEX D</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:11pt">ACDP - Guidance on prevention of CJD and vCJD by Advisory Committee on Dangerous Pathogens' Transmissible Spongiform Encephalopathy (ACDP TSE) Subgroup.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ANNEX E - </span><span style="font-family:'Times New Roman'; font-size:11pt">National Institute for Health and Clinical Excellence (NICE) - </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Patient safety and reduction of risk of transmission of Creutzfeldt–Jakob disease (CJD) via interventional procedures</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ANNEX F</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Results of latest abnormal prion protein prevalence survey Health Protection Report </span><span style="font-family:'Times New Roman'; font-size:11pt">Vol 6 No. 32 - 10 August 2012</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Annex G</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:11pt">ACDP - </span><span style="font-family:'Times New Roman'; font-size:11pt">Position Statement on occurrence of vCJD and prevalence of infection in the UK population</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ANNEX H</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:11pt">M</span><span style="font-family:'Times New Roman'; font-size:11pt">apping out the co</span><a name="_GoBack"></a><span style="font-family:'Times New Roman'; font-size:11pt">nsequences of screening blood donations for PrP</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">Sc</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ANNEX I</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Choice Framework for local Policy and Procedures (CFPP) and </span><span style="font-family:'Times New Roman'; font-size:11pt">Health Technical Memorandum (HTM) </span><span style="font-family:'Times New Roman'; font-size:11pt">Guidance</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ANNEX J</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:11pt">The role of the Medicines and </span><span style="font-family:'Times New Roman'; font-size:11pt">Healthcare </span><span style="font-family:'Times New Roman'; font-size:11pt">products </span><span style="font-family:'Times New Roman'; font-size:11pt">Regulatory Agency </span><span style="font-family:'Times New Roman'; font-size:11pt">(</span><span style="font-family:'Times New Roman'; font-size:11pt">MHRA</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Annex K</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO - </span><span style="font-family:'Times New Roman'; font-size:11pt">Guidance on the Microbiological Safety of Human Organs, Tissues and Cells used in Transplantation</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></div><br style="clear:both; mso-break-type:section-break; page-break-before:always" /><div><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ANNEX A</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">CREUTZFELDT-JAKOB DISEASE IN THE UK (By Calendar Year)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><div style="text-align:center"><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto; width:468.95pt"><tr><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:113.4pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Referrals of Suspect CJD</span></p></td><td colspan="6" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:355.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Deaths of Definite and Probable CJD</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Year</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Referrals</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Year</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Sporadic</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">1</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Iatrogenic</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Genetic</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">2</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Total Deaths</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1990</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">[53]†</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1990</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">28</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">5</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">0</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">-</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">33</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1991</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">75</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1991</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">32</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">-</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">36</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1992</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">96</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1992</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">45</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">6</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">-</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">53</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1993</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">79</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1993</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">36</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">4</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">7</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">-</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">47</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1994</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">119</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1994</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">54</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">8</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">-</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">63</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1995</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">87</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1995</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">35</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">4</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">5</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">47</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1996</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">133</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1996</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">40</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">4</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">6</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">10</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">60</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1997</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">163</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1997</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">59</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">6</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">6</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">10</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">81</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1998</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">155</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1998</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">64</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">5</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">18</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">90</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1999</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">170</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1999</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">62</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">6</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">15</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">85</span></p></td></tr><tr><td style="border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2000</span></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">178</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2000</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">50</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">28</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">82</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2001</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">179</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2001</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">58</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">4</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">6</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">20</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">88</span></p></td></tr><tr><td style="border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2002</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">164</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2002</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">73</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">0</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">5</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">17</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">95</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2003</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">162</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2003</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">79</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">5</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">6</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">18</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">108</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2004</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">114</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2004</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">50</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">6</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">9</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">67</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2005</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">124</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2005</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">67</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">4</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">13</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">5</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">89</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2006</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">112</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2006</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">68</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">9</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">5</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">83</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2007</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">119</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2007</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">64</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">10</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">5</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">81</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2008</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">150</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2008</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">86</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">5</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">5</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">98</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2009</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:double; border-right-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">153</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2009</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">80</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">8</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">93</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2010</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:double; border-right-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">150</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2010</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">85</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">7</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">98</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2011</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:double; border-right-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">157</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2011</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">90</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">14</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">5</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">112</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2012</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:double; border-right-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">12</span><span style="font-family:'Times New Roman'; font-size:11pt">5</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2012</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">92</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">5</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">11</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">0</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">108</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2013*</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:double; border-right-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1</span><span style="font-family:'Times New Roman'; font-size:11pt">44</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2013</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">80</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">5</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">87</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:double; border-top-width:1.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Total Referrals</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-top-color:#000000; border-top-style:double; border-top-width:1.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">31</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">61</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:double; border-right-width:1.5pt; border-top-color:#000000; border-top-style:double; border-top-width:1.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:49.95pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Total Deaths</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-left-color:#000000; border-left-style:double; border-left-width:1.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:double; border-top-width:1.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">14</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">77</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:double; border-top-width:1.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.75pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">74</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:double; border-top-width:1.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:56.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">156</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:double; border-top-width:1.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:42.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">177</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:double; border-top-width:1.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:71.7pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">18</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">84</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt"><td style="width:56.7pt; border:none"></td><td style="width:56.7pt; border:none"></td><td style="width:49.95pt; border:none"></td><td style="width:70.9pt; border:none"></td><td style="width:63.75pt; border:none"></td><td style="width:56.7pt; border:none"></td><td style="width:42.55pt; border:none"></td><td style="width:71.7pt; border:none"></td></tr><![endif]--></table></div><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">† </span><span style="font-family:'Times New Roman'; font-size:11pt">Referral figure for 1990 is from 1 May onwards</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">*</span><span style="font-family:'Times New Roman'; font-size:11pt"> As at </span><span style="font-family:'Times New Roman'; font-size:11pt">7</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">th</span><span style="font-family:'Times New Roman'; font-size:11pt"> January </span><span style="font-family:'Times New Roman'; font-size:11pt">201</span><span style="font-family:'Times New Roman'; font-size:11pt">4</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><h1 style="margin:0pt; page-break-after:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Summary of vCJD cases</span></h1><h1 style="margin:0pt; page-break-after:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Deaths</span></h1><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Deaths from definite vCJD (confirmed):</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">122</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Deaths from probable vCJD (without neuropathological confirmation):</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">  55</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Deaths from probable vCJD (neuropathological confirmation pending):</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">    0</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Number of deaths from definite or probable vCJD (as above):</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">177</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 14.2pt; text-align:justify; text-indent:-14.2pt"><span style="font-family:'Times New Roman'; font-size:7.33pt; font-weight:bold; vertical-align:super">1</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:11pt">There are</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">in addition a total of 9 cases of </span><span style="font-family:'Times New Roman'; font-size:11pt">variably protease-sensitive prionopathy (VPSPr) </span><span style="font-family:'Times New Roman'; font-size:11pt">(death</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> in 1997(1 case), 2004(1), 2006(1), 2008(2), 2012(4)) not included in the above figures.</span></p><p style="margin:0pt 0pt 0pt 14.2pt; text-align:justify; text-indent:-14.2pt"><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">2</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Includes </span><span style="font-family:'Times New Roman'; font-size:11pt">all genetic prion disease, including </span><span style="font-family:'Times New Roman'; font-size:11pt">Gerstmann–Sträussler–Scheinker syndrome (GSS)</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p></div><br style="clear:both; mso-break-type:section-break; page-break-before:always" /><div><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ANNEX B</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><img src="data:image/png;base64,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" width="949" height="501" alt="" /></p><p style="margin:0pt; text-align:justify"><br style="page-break-before:always; clear:both" /></p></div><br style="clear:both; mso-break-type:section-break; page-break-before:always" /><div><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ANNEX</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">C</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><img src="data:image/png;base64,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" width="221" height="89" alt="" /></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">MEASURES CURRENTLY IN PLACE IN THE UK TO REDUCE THE POTENTIAL RISK OF TRANSMITTING</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">VARIANT CREUTZFELDT-JAKOB DISEASE VIA BLOOD</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Since 1996, when the theoretical risk of transmitting variant Creutzfeldt-Jakob disease (vCJD) through blood was first identified, a series of precautionary measures approved and endorsed by independent scientific Advisory Committees have been implemented to reduce the risk to the blood supply and to products made by fractionating plasma.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">All these measures have been reviewed and endorsed by the Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO), and SaBTO publishes this document on its website for ease of reference.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The measures are summarised below.  They are applicable to all blood / blood components and blood products.  Where SaBTO has recently reviewed a measure, detailed information can be found in the published meeting papers.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">Withdrawal of blood</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Since December 1997, all blood components, plasma products or tissues obtained from any individual who later develops clinical vCJD have been withdrawn/recalled to prevent their use.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Comment</span><span style="font-family:'Times New Roman'; font-size:11pt"> – this measure continues, supported by the effective application of the </span><span style="font-family:'Times New Roman'; font-size:11pt">Transfusion Medicine Epidemiology Review (TMER) collaborative project between the UK National CJD Research and Surveillance Unit and the UK Blood Services.  TMER investigates any evidence that Creutzfeldt-Jakob disease (CJD) or variant Creutzfeldt-Jakob disease (vCJD) may have been transmitted via the blood supply.  Further information on TMER can be found at:</span></p><p style="margin:0pt 0pt 0pt 72pt; text-align:justify"><a href="http://www.cjd.ed.ac.uk/TMER/TMER.htm"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.cjd.ed.ac.uk/TMER/TMER.htm</span></a></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">Leucoreduction</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Since October 1999, white blood cells (which may carry a risk of transmitting vCJD) have been reduced in all blood used for transfusion, by a process known as leucodepletion or leucoreduction.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Comment</span><span style="font-family:'Times New Roman'; font-size:11pt"> – this measure continues; it not only provides a measure of vCJD risk reduction but additionally is crucial in supporting SaBTO’s recommendations with regard to cytomegalovirus risk reduction.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">Donor deferral</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Since April 2004, following the report of the first presumed case of transmission of vCJD by blood transfusion, individuals who had themselves received a transfusion of blood components since January 1980 were excluded from donating blood.  In July 2004, this exclusion criterion for blood donation was extended to include two other groups who had received transfusions of blood components since 1980:</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Previously transfused platelet donors</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Donors who were unsure if they had previously had a blood transfusion.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">This measure applies to donors who have been transfused anywhere in the world.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Comment</span><span style="font-family:'Times New Roman'; font-size:11pt"> – this measure continues.  Given the potential for transmission of vCJD via blood and continued uncertainties as to the implications of the prevalence of abnormal prion protein, this measure is considered important to restrict potential spread.  Each recipient acts as an end stage in any potential transmission.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">Clotting factors and immunoglobulin</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Since 1999, plasma for the manufacture of fractionated plasma products, such as clotting factors and immunoglobulins, has been obtained from non-UK sources.  Since 1998, synthetic (recombinant) clotting factor for the treatment of haemophilia has been provided to the under-16s, and since 2005 this measure has been extended to all patients for whom it is suitable.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Comment</span><span style="font-family:'Times New Roman'; font-size:11pt"> – this measure continues as a means to reduce the potential risk of transmitting vCJD (and other blood borne infections) to those with bleeding disorders and other conditions.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">Plasma sourcing</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Since 2004, fresh frozen plasma for treating those born on or after 1 January 1996 has been obtained from abroad (the USA or Austria).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Comment</span><span style="font-family:'Times New Roman'; font-size:11pt"> – this measure continues, as confirmed by SaBTO in March 2012.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The NHS has been instructed to purchase imported solvent detergent-treated pooled plasma for adult patients with thrombotic thrombocytopenic purpura.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Comment</span><span style="font-family:'Times New Roman'; font-size:11pt"> – this measure continues, as confirmed by SaBTO in March 2012.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">Platelets</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">In September 2013, SaBTO removed the requirement to produce at least 80% of platelets by apheresis, and recommended that platelet additive solution (PAS) should be used for the suspension of platelets.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Comment</span><span style="font-family:'Times New Roman'; font-size:11pt"> – This measure continues, as reducing apheresis and using platelet additive solution provides additional, cost-effective risk reduction.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">Cryoprecipitate</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">From 2005, cryoprecipitate produced from methylene blue treated plasma imported from the USA is being used for children up to the age of 16.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Comment</span><span style="font-family:'Times New Roman'; font-size:11pt"> – this measure continues, and may be reviewed by SaBTO if new information about alternative products becomes available.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">SaBTO</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">December 2013</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ANNEX D</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ADVISORY COMMITTEE ON DANGEROUS PATHOGENS</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Guidance on prevention of CJD and vCJD by Advisory Committee on Dangerous Pathogens' Transmissible Spongiform Encephalopathy (ACDP TSE) Subgroup.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The following ACDP guidance documents are all publically available at:</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><a href="https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group</span></a></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209755/Part_1_-_Introduction.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">Introduction</span></a></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209756/Part_2_-_Health_and_Safety.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">Health and safety management of transmissible spongiform encephalopathy</span></a></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209757/Part_3_-_Laboratory_containment_and_control_measures.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">Laboratory containment and control measures</span></a></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">Infection control of CJD, vCJD and other human prion diseases in healthcare and community settings</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209759/Annex_A1_-_Distribution_of_TSE_infectivity.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:none">Annex A1</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">: Distribution of transmissible spongiform encephalopathy infectivity in human tissues and body fluids</span></a></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209760/Annex_A2_-_Distribution_of_infectivity_in_animal_tissue.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:none">Annex A2</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">: Distribution of infectivity in animal tissue and body fluids</span></a></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209761/Annex_B_-_Diagnostic_criteria.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:none">Annex B</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">: Diagnostic criteria</span></a></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:none">Annex C</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">: General principles of decontamination and waste disposal</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209763/Annex_D_-_Transport_of_TSE-infected_material.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:none">Annex D</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">: Transport of transmissible spongiform encephalopathy-infected material</span></a></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209764/Annex_E_-_Quarantining_of_surgical_instruments.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:none">Annex E</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">: Quarantining of surgical instruments</span></a></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209765/Annex_F_-_Endoscopy.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:none">Annex F</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">: Endoscopy</span></a></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209766/Annex_H_-_After_death.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:none">Annex H</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">: After death</span></a></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209767/Annex_I_-_Outline_protocol_for_managment_of_instruments_and_tissues.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:none">Annex I</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">: Outline protocol for management of instruments and tissues from brain biopsy procedures on patients with progressive neurological disorders</span></a></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209768/Annex_J_-_Presurgical_Assessment.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:none">Annex J</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">: Assessment to be carried out before surgery and or endoscopy to identify patients with, or at risk of, CJD or vCJD</span></a></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:none">Annex K</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">: Guidelines for pathologists and pathology laboratories for the handling of tissues from patients with, or at risk of, CJD or vCJD</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209770/Annex_L_-_Managing_CJD_vCJD_risk_in_ophthalmology.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:none">Annex L</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">: Managing CJD/vCJD risk in ophthalmology</span></a></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209780/Annex_M_-_Mananging_vCJD_risk.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:none">Annex M</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">: Managing vCJD risk in general surgery and liver transplantation</span></a></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209772/CJD_guidance_for_ophthalmologists.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">CJD guidance for ophthalmologists</span></a></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209773/Information_sheet_for_funeral_directors__relatives_and_others_following_a_CJD_death.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">Information sheet for funeral directors, relatives and others following a CJD death</span></a></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209781/Alert_to_urological_surgeons.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">Alert to urological surgeons regarding the equipment used for patients at risk of vCJD requiring transrectal prostatic biopsy</span></a></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209775/Frequently_Asked_Questions.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">Frequently asked questions</span></a></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209776/Abbreviations.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">Abbreviations</span></a></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209777/Acknowledgements.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">Acknowledgements</span></a></li></ul><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><br style="page-break-before:always; clear:both" /></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ANNEX E</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">NICE GUIDANCE</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">National Institute for Health and Clinical Excellence (NICE) - </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Patient safety and reduction of risk of transmission of Creutzfeldt–Jakob disease (CJD) via interventional procedures</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><br style="page-break-before:always; clear:both" /></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ANNEX F</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Results of latest abnormal </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">prion protein prevalence survey</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Health Protection Report </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Vol 6 No. 32 - 10 August 2012</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">HPR 32 </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">1</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Summary results of the second national survey of abnormal prion prevalence in archived appendix specimens</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">In April 2008, the Spongiform Encephalopathy Advisory Committee (SEAC) considered available prevalence data for variant Creutzfeldt-Jakob Disease (vCJD) in the British population and advised that a second appendix survey, using the same approach as a previous appendix tissue survey [1] on samples from the 1941 to 1985 birth cohort, be undertaken to further refine the estimate for the prevalence of subclinical infection [2]. The second unlinked anonymous survey of the prevalence of abnormal prion protein in archived appendix tissues has now been completed and this summary provides an update to the interim results published in September 2011 [3,4].</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The survey examined appendices by immunohistochemistry from operations conducted between 2000 and 2012 and collected from 41 hospitals throughout England. Abnormal prion accumulation was detected within the follicular dendritic cells of 16 appendices out of 32,441 suitable samples examined. None of the positive appendices have come from the 176 known vCJD cases in the UK. In line with the interim findings, the final overall prevalence estimate, 493 per million (95% Confidence Interval (CI): 282 to 801 per million), remained statistically consistent with results from the earlier appendix survey (237 per million, 95%CI 49 to 692 per million) which examined samples from operations performed between 1995 and 1999 [1]. The prevalence estimates by birth cohort were 733 per million (95% CI: 269 to 1596 per million) in those born between 1941 and 1960 and 412 per million (95% CI: 198 to 758 per million) in those born between 1961 and 1985: these results were also in line with the interim findings [3,4].</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The survey was conducted by a collaboration of the HPA, the Department of Neurodegenerative Diseases at the UCL Institute of Neurology, the Animal Health and Veterinary Laboratories Agency, the National Creutzfeldt-Jakob Disease Research and Surveillance Unit, the Histopathology Department of Derriford Hospital in Plymouth, and the MRC Prion Unit.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The final survey results have been considered by the Transmissible Spongiform Encephalopathies Risk Assessment Sub-Group of the Advisory Committee on Dangerous Pathogens, the successor to SEAC [5]. In summary, the estimated prevalence range largely overlaps that from the first survey, but </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Health Protection Report </span><span style="font-family:'Times New Roman'; font-size:11pt">Vol 6 No. 32 - 10 August 2012 is narrower with a higher central estimate (around 1 in 2000 compared with around 1 in 4000). The new survey also demonstrates the presence of prion protein across a wider birth cohort than previously.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The hypothesis that the prevalence of abnormal prions found in both appendix surveys to date is linked to the epidemic of BSE in cattle in Britain can be tested directly by studying further appendix samples archived prior to the BSE outbreak and samples from those born in 1996 or later by which time measures had been put in place to protect the food chain [5].</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">References</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1. Hilton DA, Ghani AC, Conyers L, Edwards P, McCardle L, Ritchie D, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">J Pathol </span><span style="font-family:'Times New Roman'; font-size:11pt">2004; </span><span style="font-family:'Times New Roman'; font-size:11pt">203</span><span style="font-family:'Times New Roman'; font-size:11pt">: 733-9.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2. Spongiform Encephalopathy Advisory Committee (SEAC). Position Statement. Prevalence of subclinical variant Creutzfeldt-Jakob Disease infections. August 2008. SEAC position statement.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3. HPA. Interim data from the current national survey of abnormal prion prevalence in archived appendix specimens. September 2011. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Health Protection Report </span><span style="font-family:'Times New Roman'; font-size:11pt">5</span><span style="font-family:'Times New Roman'; font-size:11pt">(36). Available at: </span><a href="http://www.hpa.org.uk/hpr/archives/2011/news3611.htm#cjd"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.hpa.org.uk/hpr/archives/2011/news3611.htm#cjd</span></a><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">4. HPA. Creutzfeldt-Jakob disease (CJD) biannual update (2012/1). February 2012. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Health Protection Report </span><span style="font-family:'Times New Roman'; font-size:11pt">6</span><span style="font-family:'Times New Roman'; font-size:11pt">(6). Available at: </span><a href="http://www.hpa.org.uk/hpr/archives/2012/hpr0612.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.hpa.org.uk/hpr/archives/2012/hpr0612.pdf</span></a><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">5. Advisory Committee on Dangerous Pathogens (ACDP) TSE Risk Assessment Subgroup. Position Statement on occurrence of vCJD and prevalence of infection in the UK population. July 2012.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Available at: </span><a href="http://www.dh.gov.uk/ab/ACDP/TSEguidance/DH_125868"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.dh.gov.uk/ab/ACDP/TSEguidance/DH_125868</span></a><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></div><br style="clear:both; mso-break-type:section-break; page-break-before:always" /><div><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ANNEX </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">G</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Advisory Committee on Dangerous Pathogens (ACDP) TSE Risk Assessment Subgroup</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Position Statement on occurrence of vCJD and prevalence of infection in the UK population</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">Preface</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Variant Creutzfeldt-Jakob Disease (vCJD) is a fatal human Transmissible Spongiform Encephalopathy (TSE).  This is a type of neurological disorder associated with the presence of an abnormal, ‘misfolded’ form of prion protein, making vCJD one of a small number of ‘prion diseases’.  It almost certainly first spread to humans via cattle infected with Bovine Spongiform Encephalopathy (BSE), or ‘Mad Cow’ disease.  To date, 176 patients in the UK have died from vCJD.  They have typically been young, with a median age of about 28 years at onset of symptoms.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Earlier fears of large numbers of vCJD deaths have fortunately not been realised, and the number of new cases each year has been in decline for several years.  However, there is evidence that many more people might be infected, while not showing any symptoms.  If these people are </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">infective</span><span style="font-family:'Times New Roman'; font-size:11pt">, the risk of ‘secondary’ (person-to-person) transmission could be greater than implied by the small number of cases seen so far.  In particular, there have been concerns about the risks of vCJD being spread via blood transfusion, and possibly through the re-use of surgical instruments.  A number of precautionary steps are in place to reduce these risks</span><a name="_ftnref11"></a><a href="#_ftn11">[11]</a><span style="font-family:'Times New Roman'; font-size:11pt">, though it appears impossible to eliminate them entirely.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Meanwhile, there remain great scientific uncertainties around the disease and its behaviour.  A key question is how the evidence on prevalence of infection in the population is to be reconciled with the small number of symptomatic, clinical cases diagnosed.  Scientific advice to the Department of Health on risk assessment is provided by the Advisory Committee on Dangerous Pathogens (ACDP) TSE Risk Assessment Subgroup.  Prompted in part by the emergence of new evidence on the prevalence of infection, the Department requested the Subgroup to set out a brief, high-level summary of what is known – and not known – about the incidence and prevalence of vCJD within the UK population.  The result is the following Position Statement, discussed at the Subgroup’s meeting on July13th 2012 and finalised through subsequent correspondence.  Its aim is to make available a summary of current thinking on some key scientific issues, aimed primarily at professional audiences.  The intention is that this statement should be revisited and updated as appropriate as new evidence becomes available.  The Subgroup will continue to provide scientific advice on the effectiveness of further precautions.</span></p><p style="margin:0pt; text-align:justify"><br style="page-break-before:always; clear:both" /><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">ACDP Position Statement</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Occurrence of vCJD</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">As of July 2012, 176 patients in the UK have been found to have definite or probable</span><a name="_ftnref12"></a><a href="#_ftn12">[12]</a><span style="font-family:'Times New Roman'; font-size:11pt"> clinical vCJD, and over 220 cases have been reported world-wide.  As with other prion diseases, development of disease is influenced by genetic factors, in particular at position (“codon”) 129 of the prion protein gene.  At this position, healthy individuals have the amino-acid methionine (termed methionine homozygous, or MM), valine (valine homozygous, or VV) or both amino-acids (methionine-valine heterozygous, or MV).  These groups comprise approximately 40%, 10% and 50% of the UK population respectively.  All those probable and definite vCJD patients who have been genetically tested, have been MM homozygous at codon 129.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The UK vCJD patients comprise a single wave of clinical cases: numbers of known onsets peaked in 1999 and deaths and diagnoses both peaked in 2000.  The most recent onset of symptoms in a UK patient was in October 2010, and there are currently no living vCJD patients in the UK</span><a name="_ftnref13"></a><a href="#_ftn13">[13]</a><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">There is strong evidence that three of the 176 UK patients were infected through red cell transfusions from donors who themselves went on to develop vCJD.  No other secondary cases have been identified to date, but the possibility of some of the other 173 patients having been infected though person-to-person transmission cannot be ruled out.  In addition, abnormal prion protein was found in spleen samples from two further patients who died of unrelated causes, one having had a red cell transfusion from a donor who developed vCJD, and another having received fractionated plasma products partly sourced from such a donor.  Though neither patient showed any symptoms of vCJD, these may well represent further transmission of infection.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">There is evidence of disease amongst the other codon 129 genotypes, making it plausible that further clinical cases may appear in the remaining 60% of the population.  One MV heterozygote patient has been classified as a </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">possible</span><span style="font-family:'Times New Roman'; font-size:11pt"> clinical case, though the diagnosis of vCJD could not be designated as “probable” or “definite” due to insufficient evidence.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Case ascertainment can never be regarded as perfect, and some clinical cases may have been missed or misdiagnosed (perhaps amongst elderly patients).  However, there is no indication of large-scale under-reporting of clinical vCJD.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Prevalence of infection</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The most recent study of prevalence of abnormal prion protein tested 32,441 appendix samples, collected during surgery on patients born between 1941 and 1985.  Of these, 16 samples were judged to be “positive”</span><a name="_ftnref14"></a><a href="#_ftn14">[14]</a><span style="font-family:'Times New Roman'; font-size:11pt">.  This indicates a central prevalence estimate very close to 1 in 2,000 in the age cohort covered, with a 95% Confidence Interval running from approximately 1 in 3,500 to 1 in 1,250.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The previous </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Hilton et al</span><span style="font-family:'Times New Roman'; font-size:11pt"> study published in 2004 tested appendix samples from a narrower cohort of patients, almost all born between 1961 and 1985.  This found three positive samples from 11,247 tested, suggesting a central prevalence estimate of approximately 1 in 4,000 with 95% Confidence Interval running from roughly 1 in 1,400 to 1 in 20,000.  Although the confidence intervals of the two studies overlap, the new study thus narrows the range considerably, as well as providing a higher central estimate.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Abnormal prion protein has </span><span style="font-family:'Times New Roman'; font-size:11pt">previously been found in tissue samples taken from all codon 129 genotypes, rather than being confined to MM homozygotes.  Two of the “positive” appendices from the Hilton </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt"> survey were from VV homozygotes, while the two asymptomatic recipients of blood products referred to earlier were both MV heterozygotes.  The new findings confirm that all genotypes are susceptible to vCJD infection.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Interpretation</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The “positive” samples found in these prevalence surveys have been compared with samples taken from vCJD patients and from individuals with known exposure to vCJD.  Unless and until there is any evidence to the contrary, positivity in these tests should be seen as indicative of vCJD infection.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">The recent appendix survey therefore provides the most reliable available indication of the prevalence of asymptomatic vCJD infection within the UK population</span><a name="_ftnref15"></a><a href="#_ftn15">[15]</a><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">There is thus an increasingly marked divergence between the estimated prevalence of vCJD infection and the observed number of clinical cases.  This divergence would be even greater, were the test procedure used in the survey considered to have a sensitivity significantly below 100%.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The observation that clinical cases have so far been confined to MM homozygotes is insufficient to explain this divergence.  For example, if exposure to BSE had infected 1 person in 2,000 in the 1941-85 birth cohort, and if all infected MMs had had incubation periods similar to those seen so far, some thousands of MM cases would already have appeared</span><a name="_ftnref16"></a><a href="#_ftn16">[16]</a><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The working assumption is that the bulk of the infections identified by the appendix survey would have been caused by dietary exposure to BSE in cattle</span><a name="_ftnref17"></a><a href="#_ftn17">[17]</a><span style="font-family:'Times New Roman'; font-size:11pt">.  The fundamental linkage to BSE can be tested by examining samples collected prior to the BSE outbreak.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Given the assumed significance of exposure to BSE, prevalence of vCJD infection should be much lower amongst those born from 1996 onward, given the measures by then in place to protect the food chain.  This proposition can also be tested directly, by studying tissue samples from this post-1996 birth cohort.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Taken together, the evidence on prevalence of infection and clinical case numbers implies that even amongst MMs, only a minority of those infected develop clinical symptoms within about 20 years of primary infection.  The remainder go into a long-term, asymptomatic state.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">There may be many reasons for differences in individual response to vCJD infection, and these have yet to be fully understood.  One suggestion is that cross-species transmission (as when vCJD originated from BSE), generates </span><span style="font-family:'Times New Roman'; font-size:11pt">multiple strains of the infectious agent with different characteristics.  In any case, the development of disease following infection is likely to depend on a complex interaction between the infective agent and the individual.  Key factors may include the dose and route of infection, while individual characteristics affecting susceptibility to clinical disease include codon 129 genotype and possibly other genetic factors.  Onset of prion disease may also be triggered, or inhibited, by other conditions.  The understanding needed to disentangle the possible causal factors does not yet exist.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Whatever the reasons for infected individuals entering a long term asymptomatic state, much depends on whether this could be expected to last indefinitely, or eventually lead to clinical symptoms.  This is presently an open question, given the single wave of MM cases observed.  The precautionary assumption is that </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">further clinical cases may appear after much longer incubation periods than those seen so far</span><a name="_ftnref18"></a><a href="#_ftn18">[18]</a><span style="font-family:'Times New Roman'; font-size:11pt">, though their number could be significantly reduced by intervening deaths from other causes.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Secondary transmission</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Moving onto the risks of secondary (person-to-person) transmission, the precautionary assumption is that </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">presence of abnormal prion protein is indicative of vCJD infectivity</span><span style="font-family:'Times New Roman'; font-size:11pt"> - that positivity of an appendix sample implies that blood and other peripheral tissues would be infective.  Those with long-term asymptomatic vCJD infection would thus be potential sources of secondary infection – in particular though donation of blood or tissues and via the re-use of surgical instruments.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">It is also reasonable to assume that all those exposed to the vCJD agent by such routes would be susceptible to infection, given the detection of abnormal prion protein in all codon 129 genotypes (though the degree of susceptibility to infection, and to the onset of clinical disease, may well vary markedly between individuals).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Given the available evidence on key factors such as the infectivity of blood and tissues, and on the efficacy of instrument decontamination and measures such as leucodepletion of blood, one would expect some hundreds of secondary infections to have occurred every year, from the mid-1990s onward.  As already noted, </span><span style="font-family:'Times New Roman'; font-size:11pt">three of the 176 known vCJD patients are believed to have arisen from blood-borne infection (all through transfusion of non-leucodepleted red cells prior to1999), whilst no clinical cases have been linked to surgery.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">It remains possible that a few further vCJD patients could have been infected by secondary transmission, whist the expected </span><span style="font-family:'Times New Roman'; font-size:11pt">numbers of secondary clinical cases would be significantly reduced by the limited survival and life expectancy of patients undergoing blood transfusion or neurosurgery.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Nevertheless, the contrast between predicted numbers of infections and the appearance of clinical cases that might be attributed to secondary transmission is again striking.  A number of explanations are possible, perhaps in combination.  For example, infectivity in tissues may be lower than currently assumed, or appear at these levels only close to the onset of clinical symptoms.  Surgery may turn out to be a relatively inefficient route of infection.  Leucodepletion may have had a substantial impact on blood-borne transmission risks.  Nevertheless, it remains plausible that secondary infections are occurring in significant numbers and that (as with primary infection) many</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">infected individuals enter a long-term asymptomatic state.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">As before, it is an open question as to whether or not these individuals would eventually develop symptoms, or are non-susceptible to development of clinical vCJD.  In either case, the precautionary assumption is that while asymptomatic, they would represent possible sources of further onward infection.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Conclusions</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Clearly, many scientific uncertainties remain, and it is challenging to interpret case numbers and prevalence estimates when so much remains to be known about the course of the disease and the factors that affect it.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">While fundamental research into prion diseases continues, it is essential to ensure that consistent, long-term surveillance of the population continues.  This should include development of methods to characterise the disease and if appropriate differentiate between strains.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Despite the welcome fall in vCJD diagnoses, the indication of relatively widespread, albeit “silent”, vCJD infection necessitates continued attention to the risks of secondary, person-to-person transmission, and for applied research to support the development and implementation of risk management strategies.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Gaining further information on prevalence of infection also remains a key area, especially through the investigation of tissues from groups unexposed to BSE and of the feasibility of surveying the prevalence of abnormal prion protein in blood.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Source material</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Béringue V </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">.  (2012): Facilitated cross-species transmission of prions in extraneural tissue.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Science</span><span style="font-family:'Times New Roman'; font-size:11pt">, 27 January 2012, 335:472-5</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Bishop, M.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">., (2006): Predicting susceptibility and incubation time of human-to-human transmission of vCJD.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">The Lancet Neurology</span><span style="font-family:'Times New Roman'; font-size:11pt">, 5(5), pp.393-398.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Bruce, ME.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">., (1997): Transmissions to mice indicate that “new variant” CJD is caused by the BSE agent.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Nature</span><span style="font-family:'Times New Roman'; font-size:11pt">, 389(6650), pp.498-501.</span></li><li style="background-color:#ffffff; font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Clewley J, Kelly CM, Andrews N, Vogliqi K, Mallinson G, Kaisar M, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">.  (2009) </span><a href="http://www.bmj.com/content/338/bmj.b1442.abstract"><span style="font-family:'Times New Roman'; font-size:11pt">Prevalence of disease related prion protein in anonymous tonsil specimens in Britain: cross sectional opportunistic survey</span></a><span style="font-family:'Times New Roman'; font-size:11pt">.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">BMJ</span><span style="font-family:'Times New Roman'; font-size:11pt">; </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">338</span><span style="font-family:'Times New Roman'; font-size:11pt">: b1442.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><a href="http://www.sciencemag.org/search?author1=John+Collinge&amp;sortspec=date&amp;submit=Submit"><span style="font-family:'Times New Roman'; font-size:11pt">Collinge</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> J and </span><a href="http://www.sciencemag.org/search?author1=Anthony+R.+Clarke&amp;sortspec=date&amp;submit=Submit"><span style="font-family:'Times New Roman'; font-size:11pt">Clarke</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> AR (2007): </span><span style="font-family:'Times New Roman'; font-size:11pt">A general model of prion Strains and their pathogenicity.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Science</span><span style="font-family:'Times New Roman'; font-size:11pt"> 318: 930-936 DOI: 10.1126/science.1138718</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Collinge J (2012): The risk of prion zoonoses.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Science</span><span style="font-family:'Times New Roman'; font-size:11pt">, 27</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">th</span><span style="font-family:'Times New Roman'; font-size:11pt"> January 2012, 335:411-413</span></li><li style="background-color:#ffffff; font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Frosh A, Smith LC, Jackson CJ, Linehan JM, Brandner S, Wadsworth JDF, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">.  (2004): </span><a href="http://www.ncbi.nlm.nih.gov/pubmed/15464187?dopt=Abstract"><span style="font-family:'Times New Roman'; font-size:11pt">Analysis of 2000 consecutive UK tonsillectomy specimens for disease-related prion protein</span></a><span style="font-family:'Times New Roman'; font-size:11pt">.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">364</span><span style="font-family:'Times New Roman'; font-size:11pt">: 1260-2.</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Ghani AC and Garske T (2010): Uncertainty in the tail of the Variant Creutzfeldt-Jakob Disease epidemic in the UK.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:normal">PLoS ONE</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> 5(12) e 15626</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Head, MW </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">., (2009): Pathological investigation of the first blood donor and recipient pair linked by transfusion-associated variant Creutzfeldt–Jakob disease transmission.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Neuropathology and Applied Neurobiology</span><span style="font-family:'Times New Roman'; font-size:11pt">, 35(4), pp.433-436.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Hilton DA, Ghani AC, Conyers L </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt"> (2004): Prevalence of lymphoreticular prion protein accumulation in UK tissue samples.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">J Pathol</span><span style="font-family:'Times New Roman'; font-size:11pt"> 203: 733-9</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">HPA </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Health Protection Report</span><span style="font-family:'Times New Roman'; font-size:11pt">. Volume 6 No 32; 10 August 2012</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Ironside, JW (2006): Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">BMJ</span><span style="font-family:'Times New Roman'; font-size:11pt">, 332, pp.1186-1188.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Kaski, D </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.  </span><span style="font-family:'Times New Roman'; font-size:11pt">(2009): Variant CJD in an individual heterozygous for PRNP codon 129.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet</span><span style="font-family:'Times New Roman'; font-size:11pt">, 374(9707), p.2128.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Llewelyn, CA </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.  </span><span style="font-family:'Times New Roman'; font-size:11pt">(2004): Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet</span><span style="font-family:'Times New Roman'; font-size:11pt">, 363(9407), pp.417-421.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Mackay G, Knight RSG and Ironside J (2011): The molecular epidemiology of variant CJD.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Int Mol Epidemiol Genet</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2(3): 217-227</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">de Marco MF, Linehan J, Gill ON, Clewley JP and Brander S (2010): Large-scale immunohistochemical examination for lymphoreticular prion protein in tonsil specimens collected in Britain.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:normal">Jnl of Pathology</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> 222: 380-387</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">McCutcheon S, Alejo Blanco AR, Houston EF </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt"> (2011): </span><span style="font-family:'Times New Roman'; font-size:11pt">All Clinically-Relevant blood components transmit prion disease following a single blood transfusion: a sheep model of vCJD.  </span><span style="font-family:'Times New Roman'; font-size:11pt">PLoS One. </span><span style="font-family:'Times New Roman'; font-size:11pt">2011; </span><span style="font-family:'Times New Roman'; font-size:11pt">6</span><span style="font-family:'Times New Roman'; font-size:11pt">(8)</span><span style="font-family:'Times New Roman'; font-size:11pt">: e23169. </span><span style="font-family:'Times New Roman'; font-size:11pt">Published online 2011 August 17. doi: </span><a href="http://dx.crossref.org/10.1371%2Fjournal.pone.0023169" target="pmc_ext"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">10.1371/journal.pone.0023169</span></a></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Peden, A </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">.  (2010): Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Haemophilia</span><span style="font-family:'Times New Roman'; font-size:11pt">, 16(2), pp.296-304.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Peden, AH </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">.  (2004): Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">The Lancet</span><span style="font-family:'Times New Roman'; font-size:11pt">, 364(9433), pp.527-529.</span></li><li style="background-color:#ffffff; font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Spongiform Encephalopathy Advisory Committee (SEAC).  Position Statement.  Prevalence of subclinical variant Creutzfeldt-Jakob Disease infections.  August 2008.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Will, B (2010): Variant CJD: where has it gone, or has it? </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Practical Neurology</span><span style="font-family:'Times New Roman'; font-size:11pt">, 10(5), pp.250-251.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Wroe, SJ </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.  </span><span style="font-family:'Times New Roman'; font-size:11pt">(2006): Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report.  </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet</span><span style="font-family:'Times New Roman'; font-size:11pt">, 368(9</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Advisory Committee on Dangerous Pathogens</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">July 2012</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></div><br style="clear:both; mso-break-type:section-break; page-break-before:always" /><div><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ANNEX</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> H</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Mapping out the consequences of screening blood donations</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> for</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">PrP</span><span style="font-family:'Times New Roman'; font-size:7.33pt; font-weight:bold; vertical-align:super">Sc</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; vertical-align:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><br style="page-break-before:always; clear:both" /></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ANNEX I</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Choice Framework for local Policy and Procedures (CFPP) </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Health Technical Memorandum (HTM) </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Guidance</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The following documents are enclosed as </span><span style="font-family:'Times New Roman'; font-size:11pt">separate </span><span style="font-family:'Times New Roman'; font-size:11pt">pdf attachments:</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Choice Framework for local Policy and Procedures 01-01 – Management and decontamination of surgical instruments (medical devices) used in acute care. Part A: The formulation of local policy and choices</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Choice Framework for local Policy and Procedures 01-01 – Management and decontamination of surgical instruments (medical devices) used in acute care. Part B: Common elements</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Choice Framework for local Policy and Procedures 01-01 – Management and decontamination of surgical instruments (medical devices) used in acute care. Part C: Steam sterilization</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Choice Framework for local Policy and Procedures 01-01 – Management and decontamination of surgical instruments (medical devices) used in acute care. Part D: Washer-disinfectors</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Choice Framework for local Policy and Procedures 01-01 – Management and decontamination of surgical instruments (medical devices) used in acute care. Part E: Alternatives to steam for the sterilization of reusable medical devices</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Choice Framework for local Policy and Procedures 01-06 – Decontamination of flexible endoscopes: Operational management</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Choice Framework for local Policy and Procedures 01-06 – Decontamination of flexible endoscopes: Design and installation</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Choice Framework for local Policy and Procedures 01-06 – Decontamination of flexible endoscopes: Testing methods</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Choice Framework for local Policy and Procedures 01-06 – Decontamination of flexible endoscopes: Validation and verification</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Choice Framework for local Policy and Procedures 01-06 – Decontamination of flexible endoscopes: Policy and management</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Health Technical Memorandum 01-05: Decontamination in primary care dental practices</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><br style="page-break-before:always; clear:both" /></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ANNEX J</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">THE ROLE OF THE MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">1)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The MHRA is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe. The MHRA is a centre of the Medicines and Healthcare Products Regulatory Agency which also includes the </span><a href="http://www.nibsc.org" target="_blank"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">National Institute for Biological Standards and Control (NIBSC)</span></a><span style="font-family:'Times New Roman'; font-size:11pt">, and the </span><a href="http://www.cprd.com" target="_blank"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">Clinical Practice Research Datalink (CPRD)</span></a><span style="font-family:'Times New Roman'; font-size:11pt">. The MHRA is an executive agency of the Department of Health.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">The Regulatory Status of Blood and Blood Components</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">2)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The definition of the term ‘medicinal product’ contained in Directive 2001/83/EC excludes </span><span style="font-family:'Times New Roman'; font-size:11pt">whole blood, plasma or blood cells of human origin, except for plasma which is prepared by a method involving an industrial process. Instead, the European requirements for controlling human blood and blood components are contained in Directive 2002/98/EC and associated Directives 2004/33/EC, 2005/61/EC and 2005/62/EC. The provisions of these Directives have been transposed into UK national legislation through the Blood Safety and Quality Regulations 2005 [SI 2005/50].</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Medicinal Products</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">3)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">In the UK medicinal products are regulated by the Medicines Act 1968 </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">as amended </span><span style="font-family:'Times New Roman'; font-size:11pt">and the Human Medicines Regulations 2012 </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">as amended. </span><span style="font-family:'Times New Roman'; font-size:11pt">These Regulations reflect the provisions and requirements of the Pharmaceutical Directive 2001/83/EC. In general terms a medicinal product must have a marketing authorisation or certificate of registration before it can be sold or supplied lawfully in the UK. In order to obtain a marketing authorisation an applicant must show that the product meets the requirements of safety, quality and efficacy.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">4)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">In addition the product must be manufactured by the holder of a manufacturing authorisation and distributed by the holder of a wholesale distribution authorisation. Authorisation holders are subject to a scheme of checks and inspections to assure their compliance with regulatory requirements.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">5)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Manufacturers and Distributors of medicinal products are required to follow the European Community Guidelines on Good Manufacturing Practice (GMP). The UK produces a comprehensive guide to these known as the “Orange Guide”. In addition to all the regular controls of GMP there is a specific annex for the manufacture of medicinal products derived from human blood or plasma.</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><a href="http://tern-quay.com/Orange_Guide/Annexs/EU-GMP-Vol4_Annex14.pdf"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://tern-quay.com/Orange_Guide/Annexs/EU-GMP-Vol4_Annex14.pdf</span></a></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">6)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">In 1999 the Committee on Human Medicines gave advice that UK plasma was no longer suitable for fractionation into licensed Blood Products. Consequently medicin</span><span style="font-family:'Times New Roman'; font-size:11pt">es all contain imported plasma.</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">7)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The Unlicensed Medicinal Products for Human Use (Transmissible Spongiform Encephalopathies)(Safety) Regulations 2003 require that any unlicensed medicinal product complies with the ‘Note for guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Medicinal Products’ as published by the European Commission in the ‘Rules Governing Medicinal Products in the European Union. These can be found at</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><a href="\\ims.gov.uk\data\DH\London\SKH\NW013\Infectious Diseases and Blood Policy\04_Blood\vCJD Inquiry, Response to Select Committee v 1.11.docx"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003700.pdf</span></a></p><p style="margin:0pt; text-align:justify"><a href="\\ims.gov.uk\data\DH\London\SKH\NW013\Infectious Diseases and Blood Policy\04_Blood\vCJD Inquiry, Response to Select Committee v 1.11.docx"></a></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><br style="page-break-before:always; clear:both" /></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">The Regulation of Blood and Blood Components</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">8)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The MHRA website contains a section “How we regulate blood” to provide information on the legislation which applies to blood and blood components. This can be found at </span><a href="http://www.mhra.gov.uk/Howweregulate/Blood/index.htm"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.mhra.gov.uk/Howweregulate/Blood/index.htm</span></a></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">9)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The </span><span style="font-family:'Times New Roman'; font-size:11pt">Blood Safety and Quality Regulations 2005 set standards of quality and safety for the collection and testing of human blood and blood components, whatever their intended purpose, and their processing, storage and distribution for transfusion. The Regulations also cover the collection and testing of blood and blood components for autologous use. In effect therefore, they cover the whole process from donor to patient. The Explanatory Memorandum to the Regulations are attached for more information. The Regulations themselves can be found at</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><a href="http://www.legislation.gov.uk/uksi/2005/50/regulation/1/made"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.legislation.gov.uk/uksi/2005/50/regulation/1/made</span></a></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">10)</span><span style="font:7.0pt 'Times New Roman'">&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">In general terms the Regulations require that a Blood Establishment must be authorised for the collection and testing of blood and blood components, and the processing, storage and distribution of blood and blood components when they are untended to be used for transfusion.  An authorisation is not required for the storage, distribution and compatibility tests on blood and blood components exclusively for use within hospital facilities. Similarly an authorisation is not required for a person carrying out the collection and testing of blood and blood components or the processing, storage and distribution of blood and blood components when they are untended to be used for transfusion if that person is doing so under a contractual arrangement with an authorisation holder or a person responsible for the management of a hospital blood bank.</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">11)</span><span style="font:7.0pt 'Times New Roman'">&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt"> A Blood Establishment authorisation will detail</span></p><p style="margin:0pt 0pt 0pt 54pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">a)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The activities to be carried out at each site</span></p><p style="margin:0pt 0pt 0pt 54pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">b)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Any contractual arrangements if activities are to be carried out by a person on behalf of the Establishment</span></p><p style="margin:0pt 0pt 0pt 54pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">c)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The name and qualifications of the responsible person for the Establishment</span></p><p style="margin:0pt 0pt 0pt 54pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">d)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">A list of the hospital blood banks supplied by the Establishment.</span></p><p style="margin:0pt 0pt 0pt 54pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">e)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The quality system in place for each site for each activity.</span></p><p style="margin:0pt 0pt 0pt 54pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">f)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The authorisation may be refused, suspended or varied if it appears that the Establishment is not capable of meeting the necessary standards or is no longer doing so. </span><span style="font-family:'Times New Roman'; font-size:11pt">There are currently (as at 13 December 2013) 12 UK Blood Establishments authorised which cover some thirty sites. These are inspected every two years. However, a</span><span style="font-family:'Times New Roman'; font-size:11pt">n authorisation holder is required to alert the MHRA should their own internal processes reveal an issue with the required standards.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">12)</span><span style="font:7.0pt 'Times New Roman'">&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt"> The Regulations require that each unit of blood or blood component is </span><span style="font-family:'Times New Roman'; font-size:11pt">labeled to</span><span style="font-family:'Times New Roman'; font-size:11pt"> contain the official name of the component, the amount of cells in the component, a unique donation indication, the name of the producing blood establishment, the blood group (unless the plasma is intended for fractionation), the Rh D Group (unless the plasma is intended for fractionation), the date or time of expiry, the temperature of storage, details of any anticoagulation or additive solution. The records of this information have to be kept for 30 years together with any other records necessary to identify each single blood donation and/or unit and to enable full traceability to the point of delivery to a hospital.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><br style="page-break-before:always; clear:both" /></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ANNEX </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">K</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">Advisory Committee on the Safety of Blood Tissue and Organs (SABTO)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Guidance on the Microbiological Safety of Human Organs, Tissues and Cells used in Transplantation</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">Transmissible Spo</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">ngiform Encephalopathies (TSEs)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">9.32 TSEs (otherwise known as prion diseases) are a group of fatal transmissible neurodegenerative disorders that in humans occur in sporadic, genetic and acquired forms. The commonest human TSE, Creutzfeldt-Jakob disease, occurs in both sporadic (sCJD) and acquired (vCJD) forms. The transmissible agent (or prion) is composed principally of a misfolded host protein, the prion protein, that accumulat</span><span style="font-family:'Times New Roman'; font-size:11pt">es at high levels in the brain.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">9.33 Over past decades, sCJD has been transmitted from one patient to another through medical or surgical procedures involving neurosurgical instruments, brain electrodes, tissue (human cornea and dura mater grafts) and tissue extracts (human pituitary hormones). There have been no known transmissions of vCJD via surgery or use of tissues or organs to date; however there has been transmission of vCJD infection via transfusion of red blood cells (4 cases) and UK plasma used t</span><span style="font-family:'Times New Roman'; font-size:11pt">o produce Factor VIII (1 case).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">9.34 Donor deferral issues centre around the potential for transmitting TSEs during organ and tissue transplantation. Deferral of donors is complex. An effective screening test for the detection of misfolded prions in donor blood is not available at present, and the prevalence of asymptomatic infected </span><span style="font-family:'Times New Roman'; font-size:11pt">persons in the UK is uncertain.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">9.35 However, there are a number of risk factors for human TSEs that have been identified, including prior exposure to human blood, dura mater grafts, pituitary-derived hormones and contaminated surgical instruments. In addition, a number of individuals have been notified that they are at increased risk of CJD/vCJD for public health purposes, due to their exposure to one or more risk factors. Guidance from the Advisory Committee on Dangerous Pathogens’ TSE Working Group is available from their website and information on notifications is on t</span><span style="font-family:'Times New Roman'; font-size:11pt">he CJD Incidents Panel website.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">9.36 Individuals with a confirmed or suspected TSE, a neurological disease of unknown aetiology or those who are blood relatives of persons with familial CJD cannot be accepted as donors of organs or tissues. However, if a donor has had two or more blood relatives develop a prion-associated disease and, following genetic counselling, they have been informed they are not at risk, the</span><span style="font-family:'Times New Roman'; font-size:11pt">y may be accepted for donation.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">9.37 Pre-exposure to human dura mater grafts, human pituitary-derived growth hormone and/or gonadotrophin excludes the donation of tissues, and should be taken into account when assessing any donor for their suitability for organ donation. There is no good evidence of transmission by organs or tissues other than by those</span><span style="font-family:'Times New Roman'; font-size:11pt"> of the central nervous system.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">9.38 For lifesaving organ and bone marrow transplantation only, donor exposure to risk factors for CJD and vCJD should be taken into account in the risk assessment, but does not</span><span style="font-family:'Times New Roman'; font-size:11pt"> necessarily preclude donation.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">9.39 Table 14 gives a summary of the exclusions from organ and/or tissue donation, </span><span style="font-family:'Times New Roman'; font-size:11pt">based on possible TSE exposure.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></div><br style="clear:both; mso-break-type:section-break; page-break-before:always" /><div><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Table – Exclusions from organ and/or tissue donation based on possible TSE exposure</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt"><tr style="height:28.25pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:182.6pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:170.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">LIVE TISSUE DONORS</span></p></td><td colspan="4" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:286.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">CADAVERIC TISSUE DONORS</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">SOLID ORGAN DONORS</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:182.6pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Bone</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:99.2pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">HSC</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:109pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Musculoskeletal (ligaments, tendons &amp; cartilage)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Bone and processed bone</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Ocular</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Skin/Heart Valves</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:182.6pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Definite, probable or possible case of human TSE, including CJD and vCJD</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:99.2pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:109pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:182.6pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Individual with a neurological disease of unknown aetiology</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:99.2pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:109pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:182.6pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Individual whose blood relatives have had familial CJD</span><span style="font-family:'Times New Roman'; font-size:6.67pt; font-weight:bold; vertical-align:super">1</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:99.2pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:109pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:182.6pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Individual “presumed infected” with vCJD</span><span style="font-family:'Times New Roman'; font-size:6.67pt; font-weight:bold; vertical-align:super">2</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:99.2pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:109pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:182.6pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Individual “at increased risk of CJD/vCJD” (for public health purposes)</span><span style="font-family:'Times New Roman'; font-size:6.67pt; font-weight:bold; vertical-align:super">3</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:99.2pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Individual assessment required</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">4</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:109pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Individual assessment required</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">4</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:182.6pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">History of definite</span><span style="font-family:'Times New Roman'; font-size:6.67pt; font-weight:bold; vertical-align:super">5</span><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold"> or probable</span><span style="font-family:'Times New Roman'; font-size:6.67pt; font-weight:bold; vertical-align:super">6</span><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold"> blood transfusion since 1980</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:99.2pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Individual assessment required</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">4</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:109pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Do not exclude if transfusion is within 1 week prior to death</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Do not exclude</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">7</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Do not exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Individual assessment required</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">4</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:182.6pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">History of receipt of </span><span style="font-family:'Times New Roman'; font-size:10pt; font-style:italic; font-weight:bold">dura mater </span><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">graft</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:99.2pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Individual assessment required</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">4</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:109pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Individual assessment required</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">4</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:182.6pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">History of defini</span><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">te receipt of tissue since 1980</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:99.2pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Individual assessment required</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">4</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:109pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Do not exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Individual assessment required</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">4</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:182.6pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">History of receipt of </span><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">pituitary </span><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">derived growth hormone and/or gonadotrophin</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:99.2pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Individual assessment required</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">4</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:109pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Individual assessment required</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">4</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:182.6pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">History of receipt of organ</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:70.9pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:99.2pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:109pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Exclude</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">Individual assessment required</span><span style="font-family:'Times New Roman'; font-size:6.67pt; vertical-align:super">4</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt"><td style="width:182.6pt; border:none"></td><td style="width:70.9pt; border:none"></td><td style="width:99.2pt; border:none"></td><td style="width:109pt; border:none"></td><td style="width:63.85pt; border:none"></td><td style="width:50.3pt; border:none"></td><td style="width:63.35pt; border:none"></td><td style="width:69.5pt; border:none"></td></tr><![endif]--></table><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 18pt 0pt 0pt"><span style="font-family:Tahoma; font-size:12pt">&#xa0;</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="margin:0pt"><a name="_ftn1"></a><a href="#_ftnref1">[1]</a><span style="font-family:Tahoma; font-size:10pt"> </span><a href="http://www.nice.org.uk/guidance/ipg196"><span style="font-family:Tahoma; font-size:10pt; text-decoration:underline">http://www.nice.org.uk/guidance/ipg196</span></a></p><p style="margin:0pt 0pt 6pt"><a name="_ftn2"></a><a href="#_ftnref2">[2]</a><span style="font-family:Tahoma; font-size:10pt"> Of these 12 showed indicative patterns of staining with more than one antibody.</span></p><p style="margin:0pt 0pt 6pt"><a name="_ftn3"></a><a href="#_ftnref3">[3]</a><span style="font-family:Tahoma; font-size:10pt"> Like the Hilton </span><span style="font-family:Tahoma; font-size:10pt; font-style:italic">et al</span><span style="font-family:Tahoma; font-size:10pt"> study, the new appendix survey used IHC to screen samples.  A large scale prospective survey of tonsil samples found no positives in 95,672 tested using a high throughput enzyme immunoassay technique (Frosh </span><span style="font-family:Tahoma; font-size:10pt; font-style:italic">et al</span><span style="font-family:Tahoma; font-size:10pt">, 2004; Clewley </span><span style="font-family:Tahoma; font-size:10pt; font-style:italic">et al</span><span style="font-family:Tahoma; font-size:10pt">, 2009).  However re-testing of 9,672 samples using IHC revealed one specimen with a strongly positive follicle (de Marco </span><span style="font-family:Tahoma; font-size:10pt; font-style:italic">et al</span><span style="font-family:Tahoma; font-size:10pt">, 2010).  It is therefore considered that IHC provides the more reliable method of detection.</span></p><p style="margin:0pt"><a name="_ftn4"></a><a href="#_ftnref4">[4]</a><span style="font-family:Tahoma; font-size:10pt"> </span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763259/"><span style="font-family:Tahoma; font-size:10pt; text-decoration:underline">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763259/</span></a></p><p style="margin:0pt; orphans:0; widows:0"><a name="_ftn5"></a><a href="#_ftnref5">[5]</a><span style="font-family:Tahoma; font-size:10pt"> </span><a href="http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947323936"><span style="font-family:Tahoma; font-size:10pt; text-decoration:underline">http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947323936</span></a></p><p style="margin:0pt; orphans:0; widows:0"><a name="_ftn6"></a><a href="#_ftnref6">[6]</a><span style="font-family:Tahoma; font-size:10pt"> </span><span style="font-family:Tahoma; font-size:10pt">Mapping out the </span><span style="font-family:Tahoma; font-size:10pt">consequences of screening blood donations for </span><span style="font-family:Arial; font-size:10pt">PrP</span><span style="font-family:Arial; font-size:6.67pt; vertical-align:super">Sc</span><span style="font-family:Tahoma; font-size:10pt"> attached at </span><span style="font-family:Tahoma; font-size:10pt; font-weight:bold">Annex H.</span></p><p style="margin:0pt"><span style="font-family:Tahoma; font-size:10pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; widows:0"><a name="_ftn7"></a><a href="#_ftnref7">[7]</a><span style="font-family:Tahoma; font-size:10pt"> </span><a href="https://www.gov.uk/government/publications/blood-borne-transmission-of-vcjd-re-examination-of-scenarios"><span style="font-family:Tahoma; font-size:10pt; text-decoration:underline">https://www.gov.uk/government/publications/blood-borne-transmission-of-vcjd-re-examination-of-scenarios</span></a></p><p style="margin:0pt"><a name="_ftn8"></a><a href="#_ftnref8">[8]</a><span style="font-family:Tahoma; font-size:10pt"> </span><a href="https://www.gov.uk/government/policy-advisory-groups/advisory-committee-on-the-safety-of-blood-tissues-and-organs"><span style="font-family:Tahoma; font-size:10pt; text-decoration:underline">https://www.gov.uk/government/policy-advisory-groups/advisory-committee-on-the-safety-of-blood-tissues-and-organs</span></a></p><p style="margin:0pt; text-align:justify"><a name="_ftn9"></a><a href="#_ftnref9">[9]</a><span style="font-family:Tahoma; font-size:10pt"> </span><a href="http://www.his.org.uk/files/3113/7908/4699/CFPP_01_01_A_Management_and_decontamination_of_surgical_instruments_medical_devices_used_in_acute_care._Part_A_The_formulation_of_local_policy_and_choices.pdf"><span style="font-family:Tahoma; font-size:10pt; text-decoration:underline">http://www.his.org.uk/files/3113/7908/4699/CFPP_01_01_A_Management_and_decontamination_of_surgical_instruments_medical_devices_used_in_acute_care._Part_A_The_formulation_of_local_policy_and_choices.pdf</span></a></p><p style="margin:0pt"><span style="font-family:Tahoma; font-size:10pt">&#xa0;</span></p><p style="margin:0pt"><a name="_ftn10"></a><a href="#_ftnref10">[10]</a><span style="font-family:Tahoma; font-size:10pt"> </span><a href="http://www.shotuk.org/shot-reports/report-summary-and-supplement-2012/"><span style="font-family:Tahoma; font-size:10pt; text-decoration:underline">http://www.shotuk.org/shot-reports/report-summary-and-supplement-2012/</span></a></p><p style="margin:0pt"><a name="_ftn11"></a><a href="#_ftnref11">[11]</a><span style="font-family:Tahoma; font-size:10pt"> For an overview of risk reduction measures related to blood see </span><a href="http://www.transfusionguidelines.org.uk/index.aspx?Publication=DL&amp;Section=12&amp;pageid=794"><span style="font-family:Tahoma; font-size:10pt; text-decoration:underline">http://www.transfusionguidelines.org.uk/index.aspx?Publication=DL&amp;Section=12&amp;pageid=794</span></a></p><p style="margin:0pt"><span style="font-family:Tahoma; font-size:10pt">, and for surgical risk reduction measures see </span><a href="http://www.dh.gov.uk/ab/ACDP/TSEguidance/index.htm"><span style="font-family:Tahoma; font-size:10pt; text-decoration:underline">http://www.dh.gov.uk/ab/ACDP/TSEguidance/index.htm</span></a></p><p style="margin:0pt"><span style="font-family:Tahoma; font-size:10pt">&#xa0;</span></p><p style="margin:0pt"><a name="_ftn12"></a><a href="#_ftnref12">[12]</a><span style="font-family:'Times New Roman'; font-size:12pt"> </span><span style="font-family:Tahoma; font-size:10pt">In this context, the terms “probable” and “definite” refer to specific criteria developed for epidemiological studies of prion disease agreed by WHO.  Details can be found on National CJD Research &amp; Surveillance Unit website at </span><a href="http://www.cjd.ed.ac.uk/criteria.htm"><span style="font-family:Tahoma; font-size:10pt; text-decoration:underline">http://www.cjd.ed.ac.uk/criteria.htm</span></a></p><p style="margin:0pt"><span style="font-family:Tahoma; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 6pt"><a name="_ftn13"></a><a href="#_ftnref13">[13]</a><span style="font-family:Tahoma; font-size:10pt"> Two remain alive in France: see </span><a href="http://www.cjd.ed.ac.uk/vcjdworld.htm"><span style="font-family:Tahoma; font-size:10pt; text-decoration:underline">http://www.cjd.ed.ac.uk/vcjdworld.htm</span></a></p><p style="margin:0pt 0pt 6pt"><span style="font-family:Tahoma; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 6pt"><a name="_ftn14"></a><a href="#_ftnref14">[14]</a><span style="font-family:Calibri; font-size:10pt"> Of these 12 showed indicative patterns of staining with more than one antibody.  For summary of results see HPA </span><span style="font-family:Calibri; font-size:10pt; font-style:italic">Health Protection Report</span><span style="font-family:Calibri; font-size:10pt">. Volume 6 No 32; 10 August 2012</span></p><p style="margin:0pt 0pt 6pt"><a name="_ftn15"></a><a href="#_ftnref15">[15]</a><span style="font-family:Tahoma; font-size:10pt"> Like the Hilton </span><span style="font-family:Tahoma; font-size:10pt; font-style:italic">et al</span><span style="font-family:Tahoma; font-size:10pt"> study, the new appendix survey used Immunohistochemisty (IHC) to screen samples.  A large scale prospective survey of tonsil samples found no positives in 95,672 tested using a high throughput enzyme immunoassay technique (Frosh </span><span style="font-family:Tahoma; font-size:10pt; font-style:italic">et al</span><span style="font-family:Tahoma; font-size:10pt">, 2004; Clewley </span><span style="font-family:Tahoma; font-size:10pt; font-style:italic">et al</span><span style="font-family:Tahoma; font-size:10pt">, 2009).  However re-testing of 9,672 samples using IHC revealed one specimen with a strongly positive follicle (de Marco </span><span style="font-family:Tahoma; font-size:10pt; font-style:italic">et al</span><span style="font-family:Tahoma; font-size:10pt">, 2010).  It is therefore considered that IHC provides the more reliable method of detection.</span></p><p style="margin:0pt 0pt 6pt"><a name="_ftn16"></a><a href="#_ftnref16">[16]</a><span style="font-family:Tahoma; font-size:10pt"> This can be illustrated by a rough calculation considering infections solely in the 1941-85 cohort.  At the height of exposure to BSE, circa 1990, this cohort comprised about 30m people, 40% (12m) of them MM homozygotes.  A prevalence of 1 in 2,000 (if due to primary infection) implies that 6,000 of these individuals would have been infected through BSE exposure.  Collectively, they would have had life-expectancy normal for their age, so there would have been only a small number of deaths due to other causes.  Had the incubation periods seen in the actual MM cases been typical of this larger MM group, most of these 6,000 infections would already have appeared as clinical cases.  This takes no account of additional infections in other genotypes or in other age cohorts.</span></p><p style="margin:0pt"><a name="_ftn17"></a><a href="#_ftnref17">[17]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Calibri; font-size:10pt">The possibility of some of the “positive” appendix samples having arisen from secondary, person-to-person transmission cannot be excluded, but this appears relatively unlikely</span><span style="font-family:Calibri; font-size:10pt">.  </span><span style="font-family:Calibri; font-size:10pt">These samples were typically taken from fairly young patients, less likely to have received blood transfusions or to have undergone prior neurosurgery.</span></p><p style="margin:0pt"><span style="font-family:Tahoma; font-size:10pt">&#xa0;</span></p><p style="margin:0pt"><a name="_ftn18"></a><a href="#_ftnref18">[18]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Calibri; font-size:10pt">Incubation</span><span style="font-family:Calibri; font-size:10pt"> Periods of over 40 years have been observed for Kuru, though these appear to be </span><span style="font-family:Calibri; font-size:10pt">extreme</span><span style="font-family:Calibri; font-size:10pt">.</span></p><p style="margin:0pt"><span style="font-family:Tahoma; font-size:10pt">&#xa0;</span></p></body></html>